C:\Program Files\Stnexp\Queries\10727911.str





L1

chain nodes :
8
ring nodes :
1 2 3 4 5 6 7 9
chain bonds :
3-8
ring bonds :
1-2 1-7 1-9 2-3 3-4 4-5 4-9 5-6 6-7
exact/norm bonds :
1-2 1-7 1-9 2-3 3-4 3-8 4-5 4-9 5-6 6-7

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:CLASS 9:Atom

C:\Program Files\Stnexp\Queries\10727911.str



L3



chain nodes :
8
ring nodes :
1 2 3 4 5 6 7 9 10
chain bonds :
3-8
ring bonds :
1-2 1-7 1-9 2-3 3-4 4-5 4-9 5-6 6-7 6-10
exact/norm bonds :
1-2 1-7 1-9 2-3 3-4 3-8 4-5 4-9 5-6 6-7 6-10

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:CLASS 9:Atom 10:Atom

```
=> d his

     (FILE 'HOME' ENTERED AT 11:07:02 ON 17 MAY 2006)

     FILE 'REGISTRY' ENTERED AT 11:07:35 ON 17 MAY 2006
L1             STRUCTURE UPLOADED
L2              35 S L1
L3             STRUCTURE UPLOADED
L4              27 S L3
L5             619 S L1 SSS FUL
L6             511 S L3  SUB=L5 FUL
L7             108 S L5 NOT L6

     FILE 'CAPLUS' ENTERED AT 11:12:07 ON 17 MAY 2006
L8               2 S L6
L9              12 S L7
L10             14 S L8 OR L9

=> d l1
L1 HAS NO ANSWERS
L1                STR
```



Structure attributes must be viewed using STN Express query preparation.

```
=> d l3
L3 HAS NO ANSWERS
L3                STR
```



Structure attributes must be viewed using STN Express query preparation.

=> d ibib abs hitstr total

L10 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:721129 CAPLUS
DOCUMENT NUMBER: 141:391789
TITLE: In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor
AUTHOR(S): Bonnefoy, Alain; Dupuis-Hamelin, Claudine; Steier, Valerie; Delachaume, Carole; Seys, Catherine; Stachyra, Therese; Fairley, Monique; Guitton, Michele; Lampilas, Maxime
CORPORATE SOURCE: Infectious Disease Group, Aventis Pharma, Romainville, 93235, Fr.
SOURCE: Journal of Antimicrobial Chemotherapy (2004), 54(2), 410-417
CODEN: JACHDX; ISSN: 0305-7453
PUBLISHER: Oxford University Press
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Production of β-lactamases is the main mechanism of β-lactam resistance in Gram-neg. bacteria. Despite the current use of clavulanic acid, sulbactam and tazobactam, the prevalence of class A and class C enzymes is increasing worldwide, demanding new β-lactamase inhibitors. Here we report the antimicrobial properties of AVE1330A (I), a representative of a novel class of bridged bicyclico[3.2.1]diazabicyclo-octanones in combination with ceftazidime. IC50 and kinetic parameters of the hydrolysis reaction were used to characterize β-lactamase inhibition by I. MICs for >600 strains were determined with the combination ceftazidime/I at a fixed ratio of 4:1. IC50s of I for TEM-1 and P99 enzymes were 0.0023 mg/L (8 nM) and 0.023 mg/L (80 nM), compared with 0.027 mg/L (130 nM) and 205.1 mg/L (1 + 106 nM) of clavulanic acid and 0.013 mg/L (40 nM) and 1.6 mg/L (5000 nM) of tazobactam. A highly stable covalent complex led to a low turnover of I. MICs of ceftazidime/I for Enterobacteriaceae were at least eight-fold lower than those of ceftazidime alone. All of the Escherichia coli, Klebsiella pneumoniae, Citrobacter and Proteus mirabilis strains, including ceftazidime-resistant isolates, were inhibited at 4-8 mg/L. Only 2 mg/L were required to inhibit other Proteus, Enterobacter, Salmonella and Serratia. The combination of ceftazidime with I exhibited broad-spectrum activity against Ambler class A- and class C-producing Enterobacteriaceae.

IT **790235-32-4**, AVE 1330A
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in vitro activity of the broad-spectrum nonlactam lactamase inhibitor AVE1330A in combination with ceftazidime)

RN 790235-32-4 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-6-sulfonic acid, 2-(aminocarbonyl)-7-oxo-, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

applicant

L10 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:472092 CAPLUS
DOCUMENT NUMBER: 141:38636
TITLE: Preparation of fused-ring diazepines as anti-bacterial drugs and inhibitors of beta-lactamases
INVENTOR(S): Lampilas, Maxime; Musicki, Branislav; Klich, Michel; Rowlands, David Alan
PATENT ASSIGNEE(S): Aventis Pharma Sa, Fr.
SOURCE: Fr. Demande, 185 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2848210	A1	20040611	FR 2002-15428	20021206
CA 2507607	AA	20040624	CA 2003-2507607	20031128
WO 2004052891	A1	20040624	WO 2003-FR3523	20031128
WO 2004052891	C1	20050728		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003294104	A1	20040630	AU 2003-294104	20031128
EP 1569935	A1	20050907	EP 2003-789523	20031128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006512335	T2	20060413	JP 2004-558137	20031128
US 2004157826	A1	20040812	US 2003-727911	20031204
PRIORITY APPLN. INFO.:			FR 2002-15428 A	20021206
			US 2003-484323P P	20030702
			WO 2003-FR3523 W	20031128

OTHER SOURCE(S): MARPAT 141:38636
GI



I



II



III

AB Title compds. I [wherein R1 = H, COOH, CN, COOR, (un)substituted CONH2, C(:NH)NH2, (CH2)mR5; R = (un)substituted alkyl, (CH2)alkenyl, aryl, arylalkyl; R5 = COOH and derivs., CN, OH, NH2 and derivs., OH and derivs.; m = 1-2; R3CCR4 = (un)substituted Ph, 5-6 membered heterocyclyl; or R4 = H, (CH2)n1R5; n1 = 0-2; and R1CCR3 = (un)substituted Ph, 5-6 membered heterocyclyl; R2 = H, halo, R, OR, NHCOR, etc.; X = -C(:O)-B-; B = -O(CH2)n2-, -NH-O- and derivs., -NH-(CH2)n2- and derivs.; n2 = 0-1; n = 1-2; and their pharmaceutically acceptable salts] were prepared as inhibitors for beta-lactamases produced by pathogenic bacteria. For example, trans-II•TEA (i.e., exo isomer) was prepared by carbonylation of aminopyridine III with diphosgene in the presence of MeCN/TEA, alkylation with benzyl bromide, OBn deprotection and sulfonation with pyridine-SO3. II exhibited IC50 values of 3 nM and 5 nM for inhibition of β-lactamases Tem-1 and P99, resp. In tests against various resistant strains of, e.g., S. aureus, selected I exhibited MIC values in the range of 0.3-40 μg/mL. Thus, pharmaceutical compns. of I and β-lactamine antibiotics are useful for treatment of bacterial infections.

IT **478624-48-5P**, 5-(Phenylmethoxy)-1-(2-propenyl)-4,5,7,8-tetrahydro-4,7-methanopyrazolo[3,4-e][1,3]diazepin-6(1H)-one **478628-75-0P**, 1-(2,3-Dihydroxypropyl)-1,4,5,8-tetrahydro-5-(phenylmethoxy)-6H-4,7-methanopyrazolo[3,4-e][1,3]diazepin-6-one **478628-76-1P** **478628-77-2P**, 1,4,5,8-Tetrahydro-1-(2-hydroxyethyl)-5-(phenylmethoxy)-6H-4,7-methanopyrazolo[3,4-e][1,3]diazepin-6-one **478628-78-3P**, 1,4,5,8-Tetrahydro-1-(2-iodoethyl)-5-(phenylmethoxy)-6H-4,7-methanopyrazolo[3,4-e][1,3]diazepin-6-one **478628-79-4P**, 4,5,6,8-Tetrahydro-6-oxo-5-(phenylmethoxy)-1H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-1-propanenitrile **478628-80-7P** **704198-34-5P**, Methyl trans-4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-1H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylate **704198-35-6P**, Methyl trans-2,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-2-(phenylmethyl)-4H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylate **704198-36-7P**, Methyl

trans-2,5,6,8-tetrahydro-5-hydroxy-6-oxo-2-(phenylmethyl)-4H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylate **704198-41-4P**, Methyl trans-4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-1-(2-phenylethyl)-1H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylate **704198-42-5P 704198-43-6P**, Methyl trans-4,5,6,8-tetrahydro-5-hydroxy-6-oxo-1-(2-phenylethyl)-1H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylate **704198-46-9P**, Methyl Trans-2,5,6,8-tetrahydro-5-hydroxy-6-oxo-2-(2-phenylethyl)-4H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylate **704198-49-2P**, Ethyl trans-4,5,6,8-tetrahydro-8-(methoxycarbonyl)-6-oxo-5-(phenylmethoxy)-1H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-1-acetate **704198-50-5P 704198-51-6P 704198-56-1P**, Methyl trans-4,5,6,8-tetrahydro-6-oxo-1-[(phenylamino)carbonyl]-5-(phenylmethoxy)-1H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylate **704198-57-2P**, Methyl trans-2,5,6,8-tetrahydro-6-oxo-2-[(phenylamino)carbonyl]-5-(phenylmethoxy)-4H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylate **704198-58-3P**, Methyl trans-2,5,6,8-tetrahydro-5-hydroxy-6-oxo-2-[(phenylamino)carbonyl]-4H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylate **704198-61-8P 704198-62-9P 704198-65-2P**, Methyl trans-2,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-2-(phenylsulfonyl)-4H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylate **704198-66-3P**, Methyl trans-2,5,6,8-tetrahydro-5-hydroxy-6-oxo-2-(phenylsulfonyl)-4H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylate **704198-69-6P**, 2-Propenyl trans-5,6-dihydro-8-(methoxycarbonyl)-6-oxo-5-(phenylmethoxy)-4H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-2(8H)-acetate **704198-70-9P**, trans-5,6-Dihydro-8-(methoxycarbonyl)-6-oxo-5-(phenylmethoxy)-4H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-2(8H)-acetic acid **704198-71-0P**, trans-5,6-Dihydro-5-hydroxy-8-(methoxycarbonyl)-6-oxo-4H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-2(8H)-acetic acid **704198-74-3P**, Methyl trans-1-(aminocarbonyl)-4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-1H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylate **704198-75-4P**, Methyl trans-2-(aminocarbonyl)-2,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-4H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylate **704198-76-5P**, Methyl trans-1-(aminocarbonyl)-4,5,6,8-tetrahydro-5-hydroxy-6-oxo-1H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylate **704198-80-1P**, Methyl trans-2-(aminocarbonyl)-2,5,6,8-tetrahydro-5-hydroxy-6-oxo-4H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylate **704198-82-3P**, 1-(2-Azidoethyl)-1,4,5,8-tetrahydro-5-(phenylmethoxy)-6H-4,7-methanopyrazolo[3,4-e][1,3]diazepin-6-one **704198-83-4P**, 1-(2-Aminoethyl)-1,4,5,8-tetrahydro-5-(phenylmethoxy)-6H-4,7-methanopyrazolo[3,4-e][1,3]diazepin-6-one **704198-84-5P**, 1,1-Dimethylethyl [2-[4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-1H-4,7-methanopyrazolo[3,4-e][1,3]diazepin-1-yl]ethyl]carbamate **704198-85-6P**, 1,1-Dimethylethyl [2-(4,5,6,8-tetrahydro-5-hydroxy-6-oxo-1H-4,7-methanopyrazolo[3,4-e][1,3]diazepin-1-yl)ethyl]carbamate **704198-90-3P**, 1-[2-[(Aminocarbonyl)oxy]ethyl]-1,4,5,8-tetrahydro-5-(phenylmethoxy)-6H-4,7-methanopyrazolo[3,4-e][1,3]diazepin-6-one **704198-91-4P**, 1-[2-[(Aminocarbonyl)oxy]ethyl]-1,4,5,8-tetrahydro-5-hydroxy-6H-4,7-methanopyrazolo[3,4-e][1,3]diazepin-6-one **704198-93-6P 704198-94-7P 704198-95-8P 704199-00-8P**, 4,5,6,8-Tetrahydro-6-oxo-5-(phenylmethoxy)-1H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-1-carboxamide **704199-01-9P**, 4,5,6,8-Tetrahydro-5-hydroxy-6-oxo-1H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-1-carboxamide **704199-03-1P 704199-10-0P**, 1,4,5,8-Tetrahydro-1-[(4-methoxyphenyl)methyl]-5-(2-propenyloxy)-6H-4,7-methanopyrazolo[3,4-e][1,3]diazepin-6-one **704199-12-2P**

704199-15-5P, trans-Methyl 4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylate **704199-16-6P**, Methyl trans-2-bromo-4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylate **704199-17-7P**, trans-Methyl 2-(4-fluorophenyl)-4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylate **704199-18-8P**, trans-Methyl 2-(4-fluorophenyl)-4,5,6,8-tetrahydro-5-hydroxy-6-oxo-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylate **704199-20-2P**, trans-Methyl 2-(4-fluorophenyl)-4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylate pyridinium salt **704199-22-4P**, trans-2-Bromo-4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid **704199-23-5P**, trans-2-Bromo-4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide **704199-24-6P**, trans-4,5,6,8-Tetrahydro-6-oxo-5-(phenylmethoxy)-2-(3-pyridinyl)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide **704199-25-7P**, trans-4,5,6,8-Tetrahydro-5-hydroxy-6-oxo-2-(3-pyridinyl)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide **704199-27-9P**, trans-4,5,6,8-Tetrahydro-6-oxo-2-(3-pyridinyl)-5-(sulfooxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide pyridinium salt **704199-29-1P**, trans-Methyl 2-Ethenyl-4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylate **704199-30-4P**, trans-Methyl 2-formyl-4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylate **704199-31-5P**, trans-Methyl 4,5,6,8-tetrahydro-2-carboxy-6-oxo-5-(phenylmethoxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylate **704199-32-6P**, trans-Methyl 2-(aminocarbonyl)-4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylate **704199-33-7P**, trans-Methyl 2-(aminocarbonyl)-4,5,6,8-tetrahydro-5-hydroxy-6-oxo-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylate **704199-35-9P**, Methyl trans-2-(aminocarbonyl)-4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylate pyridinium salt **704199-37-1P**, trans-Methyl 4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-2-[[[2-(4-pyridinyl)ethyl]amino]carbonyl]-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylate **704199-38-2P**, trans-Methyl 4,5,6,8-tetrahydro-5-hydroxy-6-oxo-2-[[[2-(4-pyridinyl)ethyl]amino]carbonyl]-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylate **704199-40-6P**, trans-Methyl 4,5,6,8-tetrahydro-6-oxo-2-[[[2-(4-pyridinyl)ethyl]amino]carbonyl]-5-(sulfooxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylate pyridinium salt **704199-42-8P**, trans-4,5,6,8-Tetrahydro-6-oxo-5-(phenylmethoxy)-2-[[[2-(4-pyridinyl)ethyl]amino]carbonyl]-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid **704199-43-9P**, trans-4,5,6,8-Tetrahydro-6-oxo-5-(phenylmethoxy)-N2-[2-(4-pyridinyl)ethyl]-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-2,8-dicarboxamide **704199-44-0P**, trans-4,5,6,8-Tetrahydro-5-hydroxy-6-oxo-N2-[2-(4-pyridinyl)ethyl]-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-2,8-dicarboxamide **704199-46-2P**, trans-4,5,6,8-Tetrahydro-6-oxo-N2-[2-(4-pyridinyl)ethyl]-5-(sulfooxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-2,8-dicarboxamide pyridinium salt **704199-48-4P**, trans-Methyl 4,5,6,8-tetrahydro-2-iodo-6-oxo-5-(phenylmethoxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylate **704199-49-5P**, trans-Methyl 4,5,6,8-tetrahydro-2-(2-methylphenyl)-6-oxo-5-(phenylmethoxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylate **704199-50-8P**, Trans 4,5,6,8-tetrahydro-2-(2-methylphenyl)-6-oxo-5-(phenylmethoxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic

acid **704199-51-9P**, trans-4,5,6,8-Tetrahydro-2-(2-methylphenyl)-6-oxo-5-(phenylmethoxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide **704199-52-0P**, trans-4,5,6,8-Tetrahydro-5-hydroxy-2-(2-methylphenyl)-6-oxo-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide **704199-54-2P**, trans-4,5,6,8-Tetrahydro-2-(2-methylphenyl)-6-oxo-5-(sulfooxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide pyridinium salt **704199-56-4P**, Methyl trans-4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-2-[2-(trifluoromethyl)phenyl]-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylate **704199-57-5P**, Trans 4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-2-[2-(trifluoromethyl)phenyl]-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid **704199-58-6P**, trans-4,5,6,8-Tetrahydro-6-oxo-5-(phenylmethoxy)-2-[2-(trifluoromethyl)phenyl]-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide **704199-59-7P**, trans-4,5,6,8-Tetrahydro-5-hydroxy-6-oxo-2-[2-(trifluoromethyl)phenyl]-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide **704199-61-1P**, trans-4,5,6,8-Tetrahydro-6-oxo-5-(sulfooxy)-2-[2-(trifluoromethyl)phenyl]-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide triethylammonium salt **704199-63-3P**, trans-Methyl 2-(2-ethylphenyl)-4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylate **704199-64-4P**, trans-2-(2-Ethylphenyl)-4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid **704199-65-5P**, trans-2-(2-Ethylphenyl)-4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide **704199-66-6P**, trans-2-(2-Ethylphenyl)-4,5,6,8-tetrahydro-5-hydroxy-6-oxo-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide **704199-68-8P**, trans-2-(2-Ethylphenyl)-4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide triethylammonium salt **704199-71-3P 704199-75-7P 704199-77-9P**, Ethyl trans-1,2,3,5-tetrahydro-3-oxo-9-[[(phenylamino)carbonyl]oxy]-2-(phenylmethoxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxylate **704199-79-1P**, trans-Ethyl 1,2,3,5-tetrahydro-2,9-dihydroxy-3-oxo-1,4-methano-4H-2,4-benzodiazepine-5-carboxylate **704199-81-5P**, Ethyl trans-1,2,3,5-tetrahydro-3-oxo-2-(phenylmethoxy)-9-[[(trifluoromethyl)sulfonyl]oxy]-1,4-methano-4H-2,4-benzodiazepine-5-carboxylate **704199-82-6P**, Ethyl trans-1,2,3,5-tetrahydro-2-hydroxy-3-oxo-9-[[(trifluoromethyl)sulfonyl]oxy]-1,4-methano-4H-2,4-benzodiazepine-5-carboxylate **704199-84-8P**, trans-Ethyl 9-(4-fluorophenyl)-1,2,3,5-tetrahydro-3-oxo-2-(phenylmethoxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxylate **704199-88-2P**, trans-Ethyl 1,2,3,5-tetrahydro-3-oxo-2-(phenylmethoxy)-8-(2-propenyloxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxylate **704199-90-6P**, trans-Ethyl 1,2,3,5-Tetrahydro-8-[(2-methoxyethoxy)methoxy]-3-oxo-2-(phenylmethoxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxylate **704199-91-7P**, trans-1,2,3,5-Tetrahydro-8-[(2-methoxyethoxy)methoxy]-3-oxo-2-(phenylmethoxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxylic acid **704199-92-8P 704199-93-9P**, trans-1,2,3,5-Tetrahydro-2-hydroxy-N-methoxy-8-[(2-methoxyethoxy)methoxy]-3-oxo-1,4-methano-4H-2,4-benzodiazepine-5-carboxamide **704199-96-2P**, Ethyl trans-8-[2-[[(1,1-dimethylethoxy)carbonyl]amino]ethoxy]-1,2,3,5-tetrahydro-3-oxo-2-(phenylmethoxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxylate **704199-97-3P**, Ethyl trans-8-[2-[[(1,1-dimethylethoxy)carbonyl]amino]ethoxy]-1,2,3,5-tetrahydro-3-oxo-2-(sulfooxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxylate sodium salt **704199-99-5P**, trans-8-[2-[[(1,1-Dimethylethoxy)carbonyl]amino]etho

xy]-1,2,3,5-tetrahydro-3-oxo-2-(phenylmethoxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxylic acid **704200-00-0P**, trans-1,1-Dimethylethyl [2-[[5-(aminocarbonyl)-1,2,3,5-tetrahydro-3-oxo-2-(phenylmethoxy)-1,4-methano-4H-2,4-benzodiazepin-8-yl]oxy]ethyl]carbamate **704200-01-1P**, trans-1,1-Dimethylethyl [2-[[5-(aminocarbonyl)-1,2,3,5-tetrahydro-3-oxo-2-(sulfooxy)-1,4-methano-4H-2,4-benzodiazepin-8-yl]oxy]ethyl]carbamate **704200-03-3P**, Ethyl trans-1,2,3,5-tetrahydro-3-oxo-8-[[(phenylamino)carbonyl]oxy]-2-(phenylmethoxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxylate **704200-04-4P**, trans-Ethyl 1,2,3,5-tetrahydro-2-hydroxy-3-oxo-8-[[(phenylamino)carbonyl]oxy]-1,4-methano-4H-2,4-benzodiazepine-5-carboxylate **704200-06-6P**, trans-Ethyl 8-[[(ethylamino)carbonyl]oxy]-1,2,3,5-tetrahydro-3-oxo-2-(phenylmethoxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxylate **704200-07-7P**, Ethyl trans-8-[[(ethylamino)carbonyl]oxy]-1,2,3,5-tetrahydro-2-hydroxy-3-oxo-1,4-methano-4H-2,4-benzodiazepine-5-carboxylate **704200-09-9P**, trans-Ethyl 1,2,3,5-tetrahydro-3-oxo-2-(phenylmethoxy)-8-[[(trifluoromethyl)sulfonyl]oxy]-1,4-methano-4H-2,4-benzodiazepine-5-carboxylate **704200-10-2P**, trans-Ethyl 8-(4-fluorophenyl)-1,2,3,5-tetrahydro-3-oxo-2-(phenylmethoxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxylate **704200-11-3P**, trans-Ethyl 8-(4-fluorophenyl)-1,2,3,5-tetrahydro-2-hydroxy-3-oxo-1,4-methano-4H-2,4-benzodiazepine-5-carboxylate **704200-13-5P**, trans-Ethyl 1,2,3,5-tetrahydro-2-hydroxy-3-oxo-8-[[(trifluoromethyl)sulfonyl]oxy]-1,4-methano-4H-2,4-benzodiazepine-5-carboxylate **704200-15-7P**, trans-Ethyl 8-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-1,2,3,5-tetrahydro-3-oxo-2-(phenylmethoxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxylate **704200-16-8P**, Trans 8-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-1,2,3,5-tetrahydro-3-oxo-2-(phenylmethoxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxylic acid **704200-17-9P**, trans-8-[(2,2-Dimethyl-1,3-dioxolan-4-yl)methoxy]-1,2,3,5-tetrahydro-3-oxo-2-(phenylmethoxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxamide **704200-18-0P**, trans-8-(2,3-Dihydroxypropoxy)-1,2,3,5-tetrahydro-3-oxo-2-(phenylmethoxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxamide **704200-19-1P**, trans-1,2,3,5-Tetrahydro-3-oxo-8-(2-oxoethoxy)-2-(phenylmethoxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxamide **704200-20-4P**, 1,2,3,5-Tetrahydro-8-(2-hydroxyethoxy)-3-oxo-2-(phenylmethoxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxamide **704200-21-5P**, trans-1,2,3,5-Tetrahydro-2-hydroxy-8-(2-hydroxyethoxy)-3-oxo-1,4-methano-4H-2,4-benzodiazepine-5-carboxamide **704200-23-7P**, trans-8-[(2,2-Dimethyl-1,3-dioxolan-4-yl)methoxy]-1,2,3,5-tetrahydro-2-hydroxy-3-oxo-1,4-methano-4H-2,4-benzodiazepine-5-carboxamide **704200-34-0P**, trans-Ethyl 3-bromo-4,6,7,8-tetrahydro-6-oxo-7-(phenylmethoxy)-5,8-methano-5H-thieno[2,3-e][1,3]diazepine-4-carboxylate **704200-35-1P**, Ethyl trans-3-(4-fluorophenyl)-4,6,7,8-tetrahydro-6-oxo-7-(phenylmethoxy)-5,8-methano-5H-thieno[2,3-e][1,3]diazepine-4-carboxylate **704200-36-2P**, trans-Ethyl 3-(4-fluorophenyl)-4,6,7,8-tetrahydro-7-hydroxy-6-oxo-5,8-methano-5H-thieno[2,3-e][1,3]diazepine-4-carboxylate **704200-38-4P**, trans-Methyl 2,5,6,8-tetrahydro-6-oxo-2-phenyl-5-(phenylmethoxy)-4H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylate **704200-39-5P**, trans-2,5,6,8-Tetrahydro-6-oxo-2-phenyl-5-(phenylmethoxy)-4H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid **704200-40-8P**, trans-2,5,6,8-Tetrahydro-6-oxo-2-phenyl-5-(phenylmethoxy)-4H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxamide **704200-41-9P**, trans-2,5,6,8-Tetrahydro-5-hydroxy-6-oxo-2-phenyl-4H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxamide **704200-43-1P**, trans-2,5,6,8-Tetrahydro-6-oxo-2-phenyl-5-(sulfooxy)-4H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxamide triethylammonium

salt **704200-50-0P**, 1,4,5,8-Tetrahydro-1-phenyl-5-(2-propenyloxy)-6H-4,7-methanopyrazolo[3,4-e][1,3]diazepin-6-one **704200-52-2P**, 1,4,5,8-Tetrahydro-1-phenyl-5-(sulfooxy)-6H-4,7-methanopyrazolo[3,4-e][1,3]diazepin-6-one 1-propenyltriphenylphosphonium salt **704200-58-8P**, trans-Methyl 4,5,6,8-tetrahydro-6-oxo-1-phenyl-5-(phenylmethoxy)-1H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylate **704200-59-9P**, trans-4,5,6,8-Tetrahydro-6-oxo-1-phenyl-5-(phenylmethoxy)-1H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid **704200-60-2P**, trans-4,5,6,8-Tetrahydro-6-oxo-1-phenyl-5-(phenylmethoxy)-1H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxamide **704200-61-3P**, trans-4,5,6,8-Tetrahydro-5-hydroxy-6-oxo-1-phenyl-1H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxamide **704200-64-6P 704200-65-7P**, trans-Ethyl 1,2,3,5-tetrahydro-3-oxo-2-(phenylmethoxy)-9-(2-propenyloxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxylate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of fused-ring diazepines as inhibitors of β-lactamases)

RN 478624-48-5 CAPLUS
CN 6H-4,7-Methanopyrazolo[3,4-e][1,3]diazepin-6-one, 1,4,5,8-tetrahydro-5-(phenylmethoxy)-1-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 478628-75-0 CAPLUS
CN 6H-4,7-Methanopyrazolo[3,4-e][1,3]diazepin-6-one, 1-(2,3-dihydroxypropyl)-1,4,5,8-tetrahydro-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 478628-76-1 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-1-acetaldehyde, 4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 478628-77-2 CAPLUS
CN 6H-4,7-Methanopyrazolo[3,4-e][1,3]diazepin-6-one, 1,4,5,8-tetrahydro-1-(2-hydroxyethyl)-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 478628-78-3 CAPLUS
CN 6H-4,7-Methanopyrazolo[3,4-e][1,3]diazepin-6-one, 1,4,5,8-tetrahydro-1-(2-iodoethyl)-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 478628-79-4 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-1-propanenitrile, 4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 478628-80-7 CAPLUS
CN 6H-4,7-Methanopyrazolo[3,4-e][1,3]diazepin-6-one, 1,4,5,8-tetrahydro-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 704198-34-5 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-, methyl ester, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704198-35-6 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 2,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-2-(phenylmethyl)-, methyl ester, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704198-36-7 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 2,5,6,8-tetrahydro-5-hydroxy-6-oxo-2-(phenylmethyl)-, methyl ester, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704198-41-4 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-6-oxo-1-(2-phenylethyl)-5-(phenylmethoxy)-, methyl ester, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704198-42-5 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 2,5,6,8-tetrahydro-6-oxo-2-(2-phenylethyl)-5-(phenylmethoxy)-, methyl ester, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704198-43-6 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-5-hydroxy-6-oxo-1-(2-phenylethyl)-, methyl ester, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704198-46-9 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 2,5,6,8-tetrahydro-5-hydroxy-6-oxo-2-(2-phenylethyl)-, methyl ester, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704198-49-2 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-1-acetic acid, 4,5,6,8-tetrahydro-8-(methoxycarbonyl)-6-oxo-5-(phenylmethoxy)-, ethyl ester, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704198-50-5 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-2(8H)-acetic acid, 5,6-dihydro-8-(methoxycarbonyl)-6-oxo-5-(phenylmethoxy)-, ethyl ester, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704198-51-6 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-1-acetic acid, 4,5,6,8-tetrahydro-5-hydroxy-8-(methoxycarbonyl)-6-oxo-, ethyl ester, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704198-56-1 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-6-oxo-1-[(phenylamino)carbonyl]-5-(phenylmethoxy)-,

methyl ester, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704198-57-2 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 2,5,6,8-tetrahydro-6-oxo-2-[(phenylamino)carbonyl]-5-(phenylmethoxy)-, methyl ester, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704198-58-3 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 2,5,6,8-tetrahydro-5-hydroxy-6-oxo-2-[(phenylamino)carbonyl]-, methyl ester, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704198-61-8 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid,

2,5,6,8-tetrahydro-6-oxo-2-[(phenylamino)carbonyl]-5-(phenylmethoxy)-, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704198-62-9 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-2,8(8H)-dicarboxamide, 5,6-dihydro-6-oxo-N2-phenyl-5-(phenylmethoxy)-, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704198-65-2 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 2,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-2-(phenylsulfonyl)-, methyl ester, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704198-66-3 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 2,5,6,8-tetrahydro-5-hydroxy-6-oxo-2-(phenylsulfonyl)-, methyl ester, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704198-69-6 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-2(8H)-acetic acid, 5,6-dihydro-8-(methoxycarbonyl)-6-oxo-5-(phenylmethoxy)-, 2-propenyl ester, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704198-70-9 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-2(8H)-acetic acid, 5,6-dihydro-8-(methoxycarbonyl)-6-oxo-5-(phenylmethoxy)-, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704198-71-0 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-2(8H)-acetic acid, 5,6-dihydro-5-hydroxy-8-(methoxycarbonyl)-6-oxo-, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704198-74-3 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 1-(aminocarbonyl)-4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-, methyl ester, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704198-75-4 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 2-(aminocarbonyl)-2,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-, methyl ester, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704198-76-5 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 1-(aminocarbonyl)-4,5,6,8-tetrahydro-5-hydroxy-6-oxo-, methyl ester, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704198-80-1 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 2-(aminocarbonyl)-2,5,6,8-tetrahydro-5-hydroxy-6-oxo-, methyl ester, (4R,7R,8R)-rel-, compd. with pyridine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 704198-79-8
CMF C10 H11 N5 O5

Relative stereochemistry.



CM 2

CRN 110-86-1
CMF C5 H5 N



RN 704198-82-3 CAPLUS
CN 6H-4,7-Methanopyrazolo[3,4-e][1,3]diazepin-6-one, 1-(2-azidoethyl)-1,4,5,8-tetrahydro-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 704198-83-4 CAPLUS
CN 6H-4,7-Methanopyrazolo[3,4-e][1,3]diazepin-6-one, 1-(2-aminoethyl)-1,4,5,8-tetrahydro-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 704198-84-5 CAPLUS
CN Carbamic acid, [2-[4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-1H-4,7-methanopyrazolo[3,4-e][1,3]diazepin-1-yl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 704198-85-6 CAPLUS
CN Carbamic acid, [2-[4,5,6,8-tetrahydro-5-hydroxy-6-oxo-1H-4,7-methanopyrazolo[3,4-e][1,3]diazepin-1-yl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 704198-90-3 CAPLUS
CN 6H-4,7-Methanopyrazolo[3,4-e][1,3]diazepin-6-one, 1-[2-[(aminocarbonyl)oxy]ethyl]-1,4,5,8-tetrahydro-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 704198-91-4 CAPLUS
CN 6H-4,7-Methanopyrazolo[3,4-e][1,3]diazepin-6-one, 1-[2-[(aminocarbonyl)oxy]ethyl]-1,4,5,8-tetrahydro-5-hydroxy- (9CI) (CA INDEX NAME)



RN 704198-93-6 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-1-acetic acid, 4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 704198-94-7 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-1-acetamide, 4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 704198-95-8 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-1-acetamide, 4,5,6,8-tetrahydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)



RN 704199-00-8 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-1-carboxamide, 4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 704199-01-9 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-1-carboxamide, 4,5,6,8-tetrahydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)



RN 704199-03-1 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-1-carboxamide, 4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-, compd. with pyridine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 704199-02-0
CMF C8 H9 N5 O6 S



CM 2

CRN 110-86-1
CMF C5 H5 N

RN 704199-10-0 CAPLUS
CN 6H-4,7-Methanopyrazolo[3,4-e][1,3]diazepin-6-one, 1,4,5,8-tetrahydro-1-[(4-methoxyphenyl)methyl]-5-(2-propenyloxy)- (9CI) (CA INDEX NAME)



RN 704199-12-2 CAPLUS
CN Phosphonium, triphenyl-1-propenyl-, salt with 1,4,5,8-tetrahydro-1-[(4-methoxyphenyl)methyl]-5-(sulfooxy)-6H-4,7-methanopyrazolo[3,4-e][1,3]diazepin-6-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 704199-11-1
CMF C15 H15 N4 O6 S



CM 2

CRN 76875-25-7
CMF C21 H20 P

RN 704199-15-5 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-, methyl ester, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-16-6 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 2-bromo-4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-, methyl ester, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-17-7 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 2-(4-fluorophenyl)-4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-, methyl ester, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-18-8 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 2-(4-fluorophenyl)-4,5,6,8-tetrahydro-5-hydroxy-6-oxo-, methyl ester, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-20-2 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 2-(4-fluorophenyl)-4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-, 8-methyl ester, (4R,7R,8S)-rel-, compd. with pyridine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 704199-19-9
CMF C16 H13 F N2 O7 S2

Relative stereochemistry.



CM 2

CRN 110-86-1
CMF C5 H5 N

RN 704199-22-4 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 2-bromo-4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-23-5 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide, 2-bromo-4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-24-6 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide, 4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-2-(3-pyridinyl)-, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-25-7 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide, 4,5,6,8-tetrahydro-5-hydroxy-6-oxo-2-(3-pyridinyl)-, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-27-9 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide, 4,5,6,8-tetrahydro-6-oxo-2-(3-pyridinyl)-5-(sulfooxy)-, (4R,7R,8S)-rel-, compd. with pyridine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 704199-26-8
CMF C14 H12 N4 O6 S2

Relative stereochemistry.



CM 2

CRN 110-86-1
CMF C5 H5 N

RN 704199-29-1 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 2-ethenyl-4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-, methyl ester, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-30-4 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 2-formyl-4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-, methyl ester, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-31-5 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-2,8-dicarboxylic acid, 4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-, 8-methyl ester, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-32-6 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 2-(aminocarbonyl)-4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-, methyl ester, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-33-7 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 2-(aminocarbonyl)-4,5,6,8-tetrahydro-5-hydroxy-6-oxo-, methyl ester, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-35-9 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 2-(aminocarbonyl)-4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-, 8-methyl ester, (4R,7R,8S)-rel-, compd. with pyridine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 704199-34-8
CMF C11 H11 N3 O8 S2

Relative stereochemistry.



CM 2

CRN 110-86-1
CMF C5 H5 N



RN 704199-37-1 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-2-[[[2-(4-pyridinyl)ethyl]amino]carbonyl]-, methyl ester, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-38-2 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-5-hydroxy-6-oxo-2-[[[2-(4-pyridinyl)ethyl]amino]carbonyl]-, methyl ester, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-40-6 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-6-oxo-2-[[[2-(4-pyridinyl)ethyl]amino]carbonyl]-5-(sulfooxy)-, 8-methyl ester, (4R,7R,8S)-rel-, compd. with pyridine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 704199-39-3
CMF C18 H18 N4 O8 S2

Relative stereochemistry.



CM 2

CRN 110-86-1
CMF C5 H5 N

RN 704199-42-8 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-2-[[[2-(4-pyridinyl)ethyl]amino]carbonyl]-, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-43-9 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-2,8-dicarboxamide,

4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-N2-[2-(4-pyridinyl)ethyl]-, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-44-0 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-2,8-dicarboxamide, 4,5,6,8-tetrahydro-5-hydroxy-6-oxo-N2-[2-(4-pyridinyl)ethyl]-, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-46-2 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-2,8-dicarboxamide, 4,5,6,8-tetrahydro-6-oxo-N2-[2-(4-pyridinyl)ethyl]-5-(sulfooxy)-, (4R,7R,8S)-rel-, compd. with pyridine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 704199-45-1
CMF C17 H17 N5 O7 S2

Relative stereochemistry.



CM 2

CRN 110-86-1
CMF C5 H5 N

RN 704199-48-4 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-2-iodo-6-oxo-5-(phenylmethoxy)-, methyl ester, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-49-5 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-2-(2-methylphenyl)-6-oxo-5-(phenylmethoxy)-, methyl ester, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-50-8 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-2-(2-methylphenyl)-6-oxo-5-(phenylmethoxy)-, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-51-9 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide, 4,5,6,8-tetrahydro-2-(2-methylphenyl)-6-oxo-5-(phenylmethoxy)-, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-52-0 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide, 4,5,6,8-tetrahydro-5-hydroxy-2-(2-methylphenyl)-6-oxo-, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-54-2 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide, 4,5,6,8-tetrahydro-2-(2-methylphenyl)-6-oxo-5-(sulfooxy)-, (4R,7R,8S)-rel-, compd. with pyridine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 704199-53-1
CMF C16 H15 N3 O6 S2

Relative stereochemistry.



CM 2

CRN 110-86-1
CMF C5 H5 N



RN 704199-56-4 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-2-[2-(trifluoromethyl)phenyl]-, methyl ester, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-57-5 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-2-[2-(trifluoromethyl)phenyl]-, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-58-6 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide, 4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-2-[2-(trifluoromethyl)phenyl]-, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-59-7 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide, 4,5,6,8-tetrahydro-5-hydroxy-6-oxo-2-[2-(trifluoromethyl)phenyl]-, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-61-1 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide, 4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-2-[2-(trifluoromethyl)phenyl]-, (4R,7R,8S)-rel-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 704199-60-0
CMF C16 H12 F3 N3 O6 S2

Relative stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



RN 704199-63-3 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 2-(2-ethylphenyl)-4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-, methyl ester, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-64-4 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 2-(2-ethylphenyl)-4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-65-5 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide, 2-(2-ethylphenyl)-4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-66-6 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide, 2-(2-ethylphenyl)-4,5,6,8-tetrahydro-5-hydroxy-6-oxo-, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-68-8 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide, 2-(2-ethylphenyl)-4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-, (4R,7R,8S)-rel-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 704199-67-7
CMF C17 H17 N3 O6 S2

Relative stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



RN 704199-71-3 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-2,8(8H)-dicarboxamide, 5,6-dihydro-5-hydroxy-6-oxo-N2-phenyl-, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-75-7 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 7-(2,3-dihydroxypropoxy)-1,3,4,5-tetrahydro-3-oxo-4-(phenylmethoxy)-, ethyl ester, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-77-9 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-3-oxo-6-[[(phenylamino)carbonyl]oxy]-4-(phenylmethoxy)-, ethyl ester, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-79-1 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-

4,6-dihydroxy-3-oxo-, ethyl ester, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-81-5 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-3-oxo-4-(phenylmethoxy)-6-[[(trifluoromethyl)sulfonyl]oxy]-, ethyl ester, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-82-6 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-4-hydroxy-3-oxo-6-[[(trifluoromethyl)sulfonyl]oxy]-, ethyl ester, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-84-8 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 6-(4-fluorophenyl)-1,3,4,5-tetrahydro-3-oxo-4-(phenylmethoxy)-, ethyl ester, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-88-2 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-3-oxo-4-(phenylmethoxy)-7-(2-propenyloxy)-, ethyl ester, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-90-6 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-7-[(2-methoxyethoxy)methoxy]-3-oxo-4-(phenylmethoxy)-, ethyl ester, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-91-7 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-7-[(2-methoxyethoxy)methoxy]-3-oxo-4-(phenylmethoxy)-, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-92-8 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 1,3,4,5-tetrahydro-N-methoxy-7-[(2-methoxyethoxy)methoxy]-3-oxo-4-(phenylmethoxy)-, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-93-9 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 1,3,4,5-tetrahydro-4-hydroxy-N-methoxy-7-[(2-methoxyethoxy)methoxy]-3-oxo-, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-96-2 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 7-[2-[[(1,1-dimethylethoxy)carbonyl]amino]ethoxy]-1,3,4,5-tetrahydro-3-oxo-4-(phenylmethoxy)-, ethyl ester, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-97-3 CAPLUS

CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 7-[2-[[(1,1-dimethylethoxy)carbonyl]amino]ethoxy]-1,3,4,5-tetrahydro-3-oxo-4-(sulfooxy)-, 1-ethyl ester, monosodium salt, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 704199-99-5 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 7-[2-[[(1,1-dimethylethoxy)carbonyl]amino]ethoxy]-1,3,4,5-tetrahydro-3-oxo-4-(phenylmethoxy)-, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704200-00-0 CAPLUS
CN Carbamic acid, [2-[[(1R,2R,5R)-1-(aminocarbonyl)-1,3,4,5-tetrahydro-3-oxo-4-(phenylmethoxy)-2,5-methano-2H-2,4-benzodiazepin-7-yl]oxy]ethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704200-01-1 CAPLUS
CN Carbamic acid, [2-[[(1R,2R,5R)-1-(aminocarbonyl)-1,3,4,5-tetrahydro-3-oxo-4-(sulfooxy)-2,5-methano-2H-2,4-benzodiazepin-7-yl]oxy]ethyl]-, C-(1,1-dimethylethyl) ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704200-03-3 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-3-oxo-7-[[(phenylamino)carbonyl]oxy]-4-(phenylmethoxy)-, ethyl ester, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704200-04-4 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-4-hydroxy-3-oxo-7-[[(phenylamino)carbonyl]oxy]-, ethyl ester, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704200-06-6 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 7-[[(ethylamino)carbonyl]oxy]-1,3,4,5-tetrahydro-3-oxo-4-(phenylmethoxy)-, ethyl ester, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704200-07-7 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 7-[[(ethylamino)carbonyl]oxy]-1,3,4,5-tetrahydro-4-hydroxy-3-oxo-, ethyl ester, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704200-09-9 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-3-

oxo-4-(phenylmethoxy)-7-[[(trifluoromethyl)sulfonyl]oxy]-, ethyl ester, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704200-10-2 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 7-(4-fluorophenyl)-1,3,4,5-tetrahydro-3-oxo-4-(phenylmethoxy)-, ethyl ester, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704200-11-3 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 7-(4-fluorophenyl)-1,3,4,5-tetrahydro-4-hydroxy-3-oxo-, ethyl ester, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704200-13-5 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-4-hydroxy-3-oxo-7-[[(trifluoromethyl)sulfonyl]oxy]-, ethyl ester, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704200-15-7 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-1,3,4,5-tetrahydro-3-oxo-4-(phenylmethoxy)-, ethyl ester, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704200-16-8 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-1,3,4,5-tetrahydro-3-oxo-4-(phenylmethoxy)-,

(1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704200-17-9 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-1,3,4,5-tetrahydro-3-oxo-4-(phenylmethoxy)-, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704200-18-0 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 7-(2,3-dihydroxypropoxy)-1,3,4,5-tetrahydro-3-oxo-4-(phenylmethoxy)-, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704200-19-1 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 1,3,4,5-tetrahydro-3-oxo-

7-(2-oxoethoxy)-4-(phenylmethoxy)-, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704200-20-4 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 1,3,4,5-tetrahydro-7-(2-hydroxyethoxy)-3-oxo-4-(phenylmethoxy)-, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704200-21-5 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 1,3,4,5-tetrahydro-4-hydroxy-7-(2-hydroxyethoxy)-3-oxo-, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704200-23-7 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 7-[(2,2-dimethyl-1,3-

dioxolan-4-yl)methoxy]-1,3,4,5-tetrahydro-4-hydroxy-3-oxo-, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704200-34-0 CAPLUS
CN 5,8-Methano-5H-thieno[2,3-e][1,3]diazepine-4-carboxylic acid, 3-bromo-4,6,7,8-tetrahydro-6-oxo-7-(phenylmethoxy)-, ethyl ester, (4R,5R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704200-35-1 CAPLUS
CN 5,8-Methano-5H-thieno[2,3-e][1,3]diazepine-4-carboxylic acid, 3-(4-fluorophenyl)-4,6,7,8-tetrahydro-6-oxo-7-(phenylmethoxy)-, ethyl ester, (4R,5R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704200-36-2 CAPLUS
CN 5,8-Methano-5H-thieno[2,3-e][1,3]diazepine-4-carboxylic acid, 3-(4-fluorophenyl)-4,6,7,8-tetrahydro-7-hydroxy-6-oxo-, ethyl ester, (4R,5R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704200-38-4 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 2,5,6,8-tetrahydro-6-oxo-2-phenyl-5-(phenylmethoxy)-, methyl ester, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704200-39-5 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 2,5,6,8-tetrahydro-6-oxo-2-phenyl-5-(phenylmethoxy)-, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704200-40-8 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxamide, 2,5,6,8-tetrahydro-6-oxo-2-phenyl-5-(phenylmethoxy)-, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704200-41-9 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxamide, 2,5,6,8-tetrahydro-5-hydroxy-6-oxo-2-phenyl-, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704200-43-1 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxamide, 2,5,6,8-tetrahydro-6-oxo-2-phenyl-5-(sulfooxy)-, (4R,7R,8R)-rel-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 704200-42-0
CMF C14 H13 N5 O6 S

Relative stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



RN 704200-50-0 CAPLUS
CN 6H-4,7-Methanopyrazolo[3,4-e][1,3]diazepin-6-one, 1,4,5,8-tetrahydro-1-phenyl-5-(2-propenyloxy)- (9CI) (CA INDEX NAME)



RN 704200-52-2 CAPLUS
CN Phosphonium, triphenyl-1-propenyl-, salt with 1,4,5,8-tetrahydro-1-phenyl-5-(sulfooxy)-6H-4,7-methanopyrazolo[3,4-e][1,3]diazepin-6-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 704200-51-1
CMF C13 H11 N4 O5 S



CM 2

CRN 76875-25-7
CMF C21 H20 P



RN 704200-58-8 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-6-oxo-1-phenyl-5-(phenylmethoxy)-, methyl ester, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704200-59-9 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-6-oxo-1-phenyl-5-(phenylmethoxy)-, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704200-60-2 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxamide, 4,5,6,8-tetrahydro-6-oxo-1-phenyl-5-(phenylmethoxy)-, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704200-61-3 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxamide, 4,5,6,8-tetrahydro-5-hydroxy-6-oxo-1-phenyl-, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704200-64-6 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepin-6-one, 4,5,6,8-tetrahydro-5-hydroxy-1-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 704200-65-7 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-3-oxo-4-(phenylmethoxy)-6-(2-propenyloxy)-, ethyl ester, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **704198-87-8 704198-97-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of fused-ring diazepines as inhibitors of β-lactamases)
RN 704198-87-8 CAPLUS
CN Carbamic acid, [2-[4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-1H-4,7-methanopyrazolo[3,4-e][1,3]diazepin-1-yl]ethyl]-, C-(1,1-dimethylethyl) ester, compd. with pyridine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 704198-86-7
CMF C14 H21 N5 O7 S



CM 2

CRN 110-86-1
CMF C5 H5 N

RN 704198-97-0 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-1-acetamide, 4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-, compd. with pyridine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 704198-96-9
CMF C9 H11 N5 O6 S



CM 2

CRN 110-86-1
CMF C5 H5 N

IT **704198-81-2P**, 1,1-Dimethylethyl [2-[4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-1H-4,7-methanopyrazolo[3,4-e][1,3]diazepin-1-yl]ethyl]carbamate sodium salt **704199-85-9P**, Ethyl 1,2,3,5-tetrahydro-3-oxo-8-hydroxy-2-(phenylmethoxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxylate **704199-89-3P**, trans-1,2,3,5-Tetrahydro-N-methoxy-8-[(2-methoxyethoxy)methoxy]-3-oxo-2-(sulfooxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxamide sodium salt
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(β-lactamases inhibitor; preparation of fused-ring diazepines as inhibitors of β-lactamases)

RN 704198-81-2 CAPLUS
CN Carbamic acid, [2-[4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-1H-4,7-methanopyrazolo[3,4-e][1,3]diazepin-1-yl]ethyl]-, C-(1,1-dimethylethyl) ester, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 704199-85-9 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-7-hydroxy-3-oxo-4-(phenylmethoxy)-, ethyl ester (9CI) (CA INDEX NAME)



RN 704199-89-3 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 1,3,4,5-tetrahydro-N-methoxy-7-[(2-methoxyethoxy)methoxy]-3-oxo-4-(sulfooxy)-, monosodium salt, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



Na

IT **704198-38-9P**, Methyl trans-2,5,6,8-tetrahydro-6-oxo-2-(phenylmethyl)-5-(sulfooxy)-4H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylate triethylammonium salt **704198-40-3P**, Methyl trans-4,5,6,8-tetrahydro-6-oxo-1-(2-phenylethyl)-5-(sulfooxy)-1H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylate triethylammonium salt **704198-45-8P**, Methyl trans-2,5,6,8-tetrahydro-6-oxo-2-(2-phenylethyl)-5-(sulfooxy)-4H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylate triethylammonium salt **704198-48-1P**, Ethyl trans-4,5,6,8-tetrahydro-8-(methoxycarbonyl)-6-oxo-5-(sulfooxy)-1H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-1-acetate triethylammonium salt **704198-53-8P**, Ethyl trans-5,6-dihydro-8-(methoxycarbonyl)-6-oxo-5-(sulfooxy)-4H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-2(8H)-acetate triethylammonium salt **704198-55-0P**, Methyl 2,5,6,8-tetrahydro-6-oxo-2-[(phenylamino)carbonyl]-5-(sulfooxy)-4H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylate triethylammonium salt **704198-60-7P**, 5,6-Dihydro-6-oxo-2-phenyl-5-(sulfooxy)-4H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-2,8(8H)-dicarboxamide triethylammonium salt **704198-64-1P**, Methyl trans-2,5,6,8-tetrahydro-6-oxo-2-(phenylsulfonyl)-5-(sulfooxy)-4H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-

8-carboxylate triethylammonium salt **704198-68-5P** **704198-73-2P**, Methyl trans-1-(aminocarbonyl)-4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-1H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylate pyridinium salt **704198-78-7P**, Methyl trans-2-(aminocarbonyl)-2,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-4H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylate pyridinium salt **704198-88-9P**, 1-(2-Aminoethyl)-1,4,5,8-tetrahydro-5-(sulfooxy)-6H-4,7-methanopyrazolo[3,4-e][1,3]diazepin-6-one sodium salt **704198-89-0P**, 1-[2-[(Aminocarbonyl)oxy]ethyl]-1,4,5,8-tetrahydro-5-(sulfooxy)-6H-4,7-methanopyrazolo[3,4-e][1,3]diazepin-6-one sodium salt **704198-92-5P**, 4,5,6,8-Tetrahydro-6-oxo-5-(sulfooxy)-1H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-1-acetamide sodium salt **704198-98-1P** **704198-99-2P**, 4,5,6,8-Tetrahydro-6-oxo-5-(sulfooxy)-1H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-1-carboxamide sodium salt **704199-04-2P**, 1,4,5,8-Tetrahydro-1-[(4-methoxyphenyl)methyl]-5-(sulfooxy)-6H-4,7-methanopyrazolo[3,4-e][1,3]diazepin-6-one sodium salt **704199-13-3P** **704199-21-3P**, trans-4,5,6,8-Tetrahydro-6-oxo-2-(3-pyridinyl)-5-(sulfooxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide sodium salt **704199-28-0P**, trans-Methyl 2-(aminocarbonyl)-4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylate sodium salt **704199-36-0P**, trans-Methyl 4,5,6,8-tetrahydro-6-oxo-2-[[[2-(4-pyridinyl)ethyl]amino]carbonyl]-5-(sulfooxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylate sodium salt **704199-41-7P**, trans-4,5,6,8-Tetrahydro-6-oxo-N2-[2-(4-pyridinyl)ethyl]-5-(sulfooxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-2,8-dicarboxamide sodium salt **704199-47-3P**, trans-4,5,6,8-Tetrahydro-2-(2-methylphenyl)-6-oxo-5-(sulfooxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide sodium salt **704199-55-3P**, trans-4,5,6,8-Tetrahydro-6-oxo-5-(sulfooxy)-2-[2-(trifluoromethyl)phenyl]-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide sodium salt **704199-62-2P**, trans-2-(2-Ethylphenyl)-4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide sodium salt **704199-69-9P**, trans-Ethyl 1,2,3,5-tetrahydro-9-hydroxy-3-oxo-2-(phenylmethoxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxylate **704199-76-8P**, trans-Ethyl 1,2,3,5-tetrahydro-3-oxo-9-[[(phenylamino)carbonyl]oxy]-2-(sulfooxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxylate sodium salt **704199-78-0P**, trans-Ethyl 1,2,3,5-tetrahydro-3-oxo-2,9-bis(sulfooxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxylate disodium salt **704199-80-4P**, trans-Ethyl 1,2,3,5-tetrahydro-3-oxo-2-(sulfooxy)-9-[[(trifluoromethyl)sulfonyl]oxy]-1,4-methano-4H-2,4-benzodiazepine-5-carboxylate sodium salt **704199-83-7P**, trans-Ethyl 9-(4-fluorophenyl)-1,2,3,5-tetrahydro-3-oxo-2-(sulfooxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxylate sodium salt **704199-94-0P**, trans-1,2,3,5-Tetrahydro-8-hydroxy-N-methoxy-3-oxo-2-(sulfooxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxamide sodium salt **704199-95-1P**, trans-Ethyl 8-(2-aminoethoxy)-1,2,3,5-tetrahydro-3-oxo-2-(sulfooxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxylate sodium salt **704199-98-4P**, trans-8-(2-Aminoethoxy)-1,2,3,5-tetrahydro-3-oxo-2-(sulfooxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxamide sodium salt **704200-02-2P**, trans-Ethyl 1,2,3,5-tetrahydro-3-oxo-8-[[(phenylamino)carbonyl]oxy]-2-(sulfooxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxylate sodium salt **704200-05-5P**, trans-Ethyl 8-[[(ethylamino)carbonyl]oxy]-1,2,3,5-tetrahydro-3-oxo-2-(sulfooxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxylate sodium salt **704200-08-8P**, trans-Ethyl 8-(4-fluorophenyl)-1,2,3,5-tetrahydro-3-oxo-2-(sulfooxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxylate sodium salt **704200-12-4P**, trans-Ethyl 1,2,3,5-tetrahydro-3-oxo-2-

(sulfooxy)-8-[[(trifluoromethyl)sulfonyl]oxy]-1,4-methano-4H-2,4-benzodiazepine-5-carboxylate sodium salt **704200-14-6P**, trans-1,2,3,5-Tetrahydro-3-oxo-2-(sulfooxy)-8-[2-(sulfooxy)ethoxy]-1,4-methano-4H-2,4-benzodiazepine-5-carboxamide disodium salt **704200-22-6P**, trans-8-[(2,2-Dimethyl-1,3-dioxolan-4-yl)methoxy]-1,2,3,5-tetrahydro-3-oxo-2-(sulfooxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxamide sodium salt **704200-24-8P**, trans-8-(2,3-Dihydroxypropoxy)-1,2,3,5-tetrahydro-3-oxo-2-(sulfooxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxamide sodium salt **704200-25-9P**, trans-Ethyl 3-(4-fluorophenyl)-4,6,7,8-tetrahydro-6-oxo-7-(sulfooxy)-5,8-methano-5H-thieno[2,3-e][1,3]diazepine-4-carboxylate sodium salt **704200-37-3P**, trans-2,5,6,8-Tetrahydro-6-oxo-2-phenyl-5-(sulfooxy)-4H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxamide sodium salt **704200-44-2P**, 1,4,5,8-Tetrahydro-1-phenyl-5-(sulfooxy)-6H-4,7-methanopyrazolo[3,4-e][1,3]diazepin-6-one sodium salt **704200-53-3P**, trans-4,5,6,8-Tetrahydro-6-oxo-1-phenyl-5-(sulfooxy)-1H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxamide sodium salt **704200-62-4P 704200-63-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(β-lactamases inhibitor; preparation of fused-ring diazepines as inhibitors of β-lactamases)

RN 704198-38-9 CAPLUS

CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 2,5,6,8-tetrahydro-6-oxo-2-(phenylmethyl)-5-(sulfooxy)-, 8-methyl ester, (4R,7R,8R)-rel-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 704198-37-8
CMF C16 H16 N4 O7 S

Relative stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



RN 704198-40-3 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-6-oxo-1-(2-phenylethyl)-5-(sulfooxy)-, 8-methyl ester, (4R,7R,8R)-rel-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 704198-39-0
CMF C17 H18 N4 O7 S

Relative stereochemistry.



m

CM 2

CRN 121-44-8
CMF C6 H15 N



RN 704198-45-8 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 2,5,6,8-tetrahydro-6-oxo-2-(2-phenylethyl)-5-(sulfooxy)-, 8-methyl ester, (4R,7R,8R)-rel-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 704198-44-7
CMF C17 H18 N4 O7 S

Relative stereochemistry.



ab

CM 2

CRN 121-44-8
CMF C6 H15 N



RN 704198-48-1 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-1-acetic acid, 4,5,6,8-tetrahydro-8-(methoxycarbonyl)-6-oxo-5-(sulfooxy)-, α-ethyl ester, (4R,7R,8R)-rel-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 704198-47-0
CMF C13 H16 N4 O9 S

Relative stereochemistry.



n

CM 2

CRN 121-44-8
CMF C6 H15 N



RN 704198-53-8 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-2(8H)-acetic acid, 5,6-dihydro-8-(methoxycarbonyl)-6-oxo-5-(sulfooxy)-, α-ethyl ester, (4R,7R,8R)-rel-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 704198-52-7
CMF C13 H16 N4 O9 S

Relative stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



RN 704198-55-0 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 2,5,6,8-tetrahydro-6-oxo-2-[(phenylamino)carbonyl]-5-(sulfooxy)-, 8-methyl ester, (4R,7R,8R)-rel-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 704198-54-9
CMF C16 H15 N5 O8 S

Relative stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



RN 704198-60-7 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-2,8(8H)-dicarboxamide, 5,6-dihydro-6-oxo-N2-phenyl-5-(sulfooxy)-, (4R,7R,8R)-rel-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 704198-59-4
CMF C15 H14 N6 O7 S

Relative stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N

RN 704198-64-1 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 2,5,6,8-tetrahydro-6-oxo-2-(phenylsulfonyl)-5-(sulfooxy)-, 8-methyl ester, (4R,7R,8R)-rel-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 704198-63-0
CMF C15 H14 N4 O9 S2

Relative stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



RN 704198-68-5 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-2(8H)-acetic acid, 5,6-dihydro-8-(methoxycarbonyl)-6-oxo-5-(sulfooxy)-, (4R,7R,8R)-rel-, compd. with pyridine (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 704198-67-4
CMF C11 H12 N4 O9 S

Relative stereochemistry.



CM 2

CRN 110-86-1
CMF C5 H5 N

RN 704198-73-2 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 1-(aminocarbonyl)-4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-, 8-methyl ester, (4R,7R,8R)-rel-, compd. with pyridine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 704198-72-1
CMF C10 H11 N5 O8 S

Relative stereochemistry.



CM 2

CRN 110-86-1
CMF C5 H5 N

RN 704198-78-7 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 2-(aminocarbonyl)-2,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-, 8-methyl ester, (4R,7R,8R)-rel-, compd. with pyridine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 704198-77-6
CMF C10 H11 N5 O8 S

Relative stereochemistry.



CM 2

CRN 110-86-1
CMF C5 H5 N

RN 704198-88-9 CAPLUS
CN 6H-4,7-Methanopyrazolo[3,4-e][1,3]diazepin-6-one, 1-(2-aminoethyl)-1,4,5,8-tetrahydro-5-(sulfooxy)-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 704198-89-0 CAPLUS
CN 6H-4,7-Methanopyrazolo[3,4-e][1,3]diazepin-6-one, 1-[2-[(aminocarbonyl)oxy]ethyl]-1,4,5,8-tetrahydro-5-(sulfooxy)-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 704198-92-5 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-1-acetamide, 2,3,4,5,6,8-hexahydro-6-oxo-5-(sulfooxy)-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 704198-98-1 CAPLUS
CN 6H-4,7-Methanopyrazolo[3,4-e][1,3]diazepin-6-one, 1,4,5,8-tetrahydro-5-(sulfooxy)-1-[2-(sulfooxy)ethyl]-, disodium salt (9CI) (CA INDEX NAME)



●2 Na

RN 704198-99-2 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-1-carboxamide, 4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-, monosodium salt (9CI) (CA INDEX NAME)



b

● Na

RN 704199-04-2 CAPLUS
CN 6H-4,7-Methanopyrazolo[3,4-e][1,3]diazepin-6-one, 1,4,5,8-tetrahydro-1-[(4-methoxyphenyl)methyl]-5-(sulfooxy)-, sodium salt (9CI) (CA INDEX NAME)



C

● Na

RN 704199-13-3 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 2-(4-fluorophenyl)-4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-, 8-methyl ester, sodium salt, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



S

● Na

RN 704199-21-3 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide, 4,5,6,8-tetrahydro-6-oxo-2-(2-pyridinyl)-5-(sulfooxy)-, monosodium salt, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 704199-28-0 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 2-ethenyl-4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-, 8-methyl ester, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-36-0 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-6-oxo-2-[[[2-(4-pyridinyl)ethyl]amino]carbonyl]-5-(sulfooxy)-, 8-methyl ester, monosodium salt, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 704199-41-7 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-2,8-dicarboxamide, 4,5,6,8-tetrahydro-6-oxo-N2-[2-(2-pyridinyl)ethyl]-5-(sulfooxy)-, monosodium salt, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 704199-47-3 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide, 4,5,6,8-tetrahydro-2-(2-methylphenyl)-6-oxo-5-(sulfooxy)-, monosodium salt, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 704199-55-3 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide, 4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-2-[2-(trifluoromethyl)phenyl]-, monosodium salt, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



e

● Na

RN 704199-62-2 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide, 2-(2-ethylphenyl)-4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-, monosodium salt, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



f

● Na

RN 704199-69-9 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-6-hydroxy-3-oxo-4-(phenylmethoxy)-, ethyl ester, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-76-8 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-3-oxo-6-[[(phenylamino)carbonyl]oxy]-4-(sulfooxy)-, 1-ethyl ester, monosodium salt, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 704199-78-0 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-3-oxo-4,6-bis(sulfooxy)-, 1-ethyl ester, disodium salt, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 Na

RN 704199-80-4 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-3-oxo-4-(sulfooxy)-6-[[(trifluoromethyl)sulfonyl]oxy]-, 1-ethyl ester, sodium salt, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 704199-83-7 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 6-(4-fluorophenyl)-1,3,4,5-tetrahydro-3-oxo-4-(sulfooxy)-, 1-ethyl ester, sodium salt, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 704199-94-0 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 1,3,4,5-tetrahydro-7-hydroxy-N-methoxy-3-oxo-4-(sulfooxy)-, monosodium salt, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 704199-95-1 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 7-(2-aminoethoxy)-1,3,4,5-tetrahydro-3-oxo-4-(sulfooxy)-, 1-ethyl ester, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 704199-98-4 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 7-(2-aminoethoxy)-1,3,4,5-tetrahydro-3-oxo-4-(sulfooxy)-, monosodium salt, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 704200-02-2 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-3-oxo-7-[[(phenylamino)carbonyl]oxy]-4-(sulfooxy)-, 1-ethyl ester, monosodium salt, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



W

● Na

RN 704200-05-5 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 7-[[(ethylamino)carbonyl]oxy]-1,3,4,5-tetrahydro-3-oxo-4-(sulfooxy)-, 1-ethyl ester, monosodium salt, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



X

● Na

RN 704200-08-8 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 7-(4-fluorophenyl)-1,3,4,5-tetrahydro-3-oxo-4-(sulfooxy)-, 1-ethyl ester, sodium salt, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 704200-12-4 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-3-oxo-4-(sulfooxy)-7-[[(trifluoromethyl)sulfonyl]oxy]-, 1-ethyl ester, sodium salt, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



y

● Na

RN 704200-14-6 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 1,3,4,5-tetrahydro-3-oxo-4-(sulfooxy)-7-[2-(sulfooxy)ethoxy]-, disodium salt, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



Z

●2 Na

RN 704200-22-6 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-1,3,4,5-tetrahydro-3-oxo-4-(sulfooxy)-, monosodium salt, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



a a

● Na

RN 704200-24-8 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 7-(2,3-dihydroxypropoxy)-1,3,4,5-tetrahydro-3-oxo-4-(sulfooxy)-, monosodium salt, (1R,2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



g

● Na

RN 704200-25-9 CAPLUS
CN 5,8-Methano-5H-thieno[2,3-e][1,3]diazepine-4-carboxylic acid, 3-(4-fluorophenyl)-4,6,7,8-tetrahydro-6-oxo-7-(sulfooxy)-, 4-ethyl ester, sodium salt, (4R,5R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



h

● Na

RN 704200-37-3 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxamide, 2,5,6,8-tetrahydro-6-oxo-2-phenyl-5-(sulfooxy)-, monosodium salt, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



i

● Na

RN 704200-44-2 CAPLUS
CN 6H-4,7-Methanopyrazolo[3,4-e][1,3]diazepin-6-one, 1,4,5,8-tetrahydro-1-phenyl-5-(sulfooxy)-, sodium salt (9CI) (CA INDEX NAME)



j

● Na

RN 704200-53-3 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxamide, 2,3,4,5,6,8-hexahydro-6-oxo-1-phenyl-5-(sulfooxy)-, monosodium salt, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 704200-62-4 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-2(8H)-acetic acid, 5,6-dihydro-8-(methoxycarbonyl)-6-oxo-5-(sulfooxy)-, (4R,7R,8R)-rel-, compd. with N,N-diethylethanamine (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 704198-67-4
CMF C11 H12 N4 O9 S

Relative stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



RN 704200-63-5 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-2,8(8H)-dicarboxamide, 5,6-dihydro-6-oxo-N2-phenyl-5-(sulfooxy)-, (4R,7R,8R)-rel-, compd. with

pyridine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 704198-59-4
CMF C15 H14 N6 O7 S

Relative stereochemistry.



CM 2

CRN 110-86-1
CMF C5 H5 N

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:592360 CAPLUS
DOCUMENT NUMBER: 139:149660
TITLE: Preparation of azabicycles as inhibitors of beta-lactamases and their use in pharmaceutical compositions containing β-lactam antibiotics
INVENTOR(S): Aszodi, Jozsef; Lampilas, Maxime; Fromentin, Claude; Rowlands, David Alan
PATENT ASSIGNEE(S): Aventis Pharma SA, Fr.
SOURCE: Fr. Demande, 152 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2835186	A1	20030801	FR 2002-951	20020128
CA 2474043	AA	20030807	CA 2003-2474043	20030127
WO 2003063864	A2	20030807	WO 2003-FR243	20030127
WO 2003063864	A3	20040311		
W: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, US, UZ, VC, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1480644	A2	20041201	EP 2003-709903	20030127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003007267	A	20041207	BR 2003-7267	20030127
JP 2005523897	T2	20050811	JP 2003-563554	20030127
CN 1655781	A	20050817	CN 2003-802878	20030127
ZA 2004005607	A	20050714	ZA 2004-5607	20040714
US 2005020572	A1	20050127	US 2004-898754	20040726
NO 2004003587	A	20040827	NO 2004-3587	20040827

PRIORITY APPLN. INFO.: FR 2002-951 A 20020128
WO 2003-FR243 W 20030127

OTHER SOURCE(S): MARPAT 139:149660
GI



I



II

AB Title compds. I [wherein R1 = H, COOH, CN, COOR, (un)substituted CONH2, C(:NH)NH2, (CH2)nR5; R = (un)substituted alkyl, (CH2)alkenyl, aryl, arylalkyl; R5 = COOH and derivs., CN, OH, NH2 and derivs., OH and derivs.; R2 = H, (CH2)n1R5; n1 = 0-2; R3 = H, alkyl; A = bond, CR4, CHR4; R4 = H, (CH2)n1R5; n = 1 or 2; X = divalent group -C(O)-B-; B = -O-(CH2)n''-, (un)substituted -NH-(CH2)n''- or (un)substituted -NHO-; n'' = 0 or 1; with the proviso that at least one of the R1, R2, or R3 is not H; and their pharmaceutically acceptable salts] were prepared as inhibitors for beta-lactamases produced by pathogenic bacteria. For example, trans-II•HCl (i.e., exo isomer) was prepared from 1-(1,1-dimethylethyl) 2-Me trans-4-amino-1,2-pyrrolidinedicarboxylate by base-catalyzed acylation with benzoyl chloride, acidulation with HCl in Et acetate, carbonylation with diphosgene in TEA, and ring formation. II exhibited IC50 values of 650 nM and 250 nM for inhibition of β-lactamases Tem-1 and P99, resp. In tests against various resistant strains of, e.g., E. coli and S. aureus, the association of cefotaxime with, e.g., the sodium salt of trans -N-[4-(dimethylamino)phenyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (an invention compound), reduced MIC values from approx. 1-40 mg/L (cefotaxime alone) to ≤ 0.04 mg/L. Thus, pharmaceutical compns. of I and β-lactamine antibiotics are useful for treatment of bacterial infections.

IT **396730-21-5P**, 5-[(1,1-Dimethylethyl)dimethylsilyl]-1,6-diazabicyclo[3-2-1]octane-7-one **396730-22-6P**, Phenylmethyl 7-oxo-1,6-diazabicyclo[3-2-1]octane-6-acetate **396730-33-9P**, 6-Hydroxy-1,6-diazabicyclo[3.2.1]octane-7-one **396730-79-3P** **396730-84-0P**, Phenylmethyl trans-7-oxo-6-[2-oxo-2-(2-propenyloxy)ethoxy]-1,6-diazabicyclo[3.2.1]octane-2-carboxylate **396731-05-8P**, Phenylmethyl 6-benzoyl-7-oxo-2-(phenylselenyl)-1,6-diazabicyclo[3.2.1]octane-2-carboxylate **396731-16-1P**, trans-7-Oxo-6-(phenylmethoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **396731-17-2P**, trans-6-Hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **396731-44-5P**, 3-Methoxy-6-(2-propenyloxy)-1,6-diazabicyclo[3.2.1]oct-3-en-7-one **396731-46-7P** **396731-52-5P**, 6-(2-Propenyloxy)-1,6-diazabicyclo[3.2.1]oct-3-en-7-one **396731-54-7P**, 1-Propenyltriphenylphosphonium salt of 6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-3-en-7-one **396731-60-5P**, 6-(Phenylmethoxy)-1,6-diazabicyclo[3.2.1]oct-3-en-7-one **396731-62-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of azabicycles as inhibitors of β-lactamases)

RN 396730-21-5 CAPLUS

CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 5-[(1,1-dimethylethyl)dimethylsilyl]- (9CI) (CA INDEX NAME)



RN 396730-22-6 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-6-acetic acid, 7-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 396730-33-9 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-hydroxy- (9CI) (CA INDEX NAME)



RN 396730-79-3 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 7-oxo-6-(2-propenyloxy)-, phenylmethyl ester, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396730-84-0 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 7-oxo-6-[2-oxo-2-(2-propenyloxy)ethoxy]-, phenylmethyl ester, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396731-05-8 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 6-benzoyl-7-oxo-2-(phenylseleno)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 396731-16-1 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 7-oxo-6-(phenylmethoxy)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396731-17-2 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 6-hydroxy-7-oxo-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396731-44-5 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]oct-3-en-7-one, 3-methoxy-6-(2-propenyloxy)- (9CI) (CA INDEX NAME)



RN 396731-46-7 CAPLUS
CN Phosphonium, triphenyl-1-propenyl-, salt with 3-methoxy-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-3-en-7-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 396731-45-6
CMF C7 H9 N2 O6 S



CM 2

CRN 76875-25-7
CMF C21 H20 P



RN 396731-52-5 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]oct-3-en-7-one, 6-(2-propenyloxy)- (9CI) (CA INDEX NAME)



RN 396731-54-7 CAPLUS
CN Phosphonium, triphenyl-1-propenyl-, salt with 6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-3-en-7-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 396731-53-6
CMF C6 H7 N2 O5 S



CM 2

CRN 76875-25-7
CMF C21 H20 P

RN 396731-60-5 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]oct-3-en-7-one, 6-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 396731-62-7 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-(sulfooxy)-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 396731-61-6
CMF C6 H10 N2 O5 S



CM 2

CRN 121-44-8
CMF C6 H15 N



IT **396730-94-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of azabicycles as inhibitors of β-lactamases)
RN 396730-94-2 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 6-benzoyl-7-oxo-, methyl ester, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **396730-16-8P**, 6-(Phenylmethyl)-1,6-diazabicyclo[3.2.1]octane-7-one **396730-24-8P**, 6-[1-(Phenylmethyl)-1H-tetrazol-5-yl]-1,6-diazabicyclo[3.2.1]octane-7-one **396730-27-1P**, 6-(Phenylmethoxy)-1,6-diazabicyclo[3.2.1]octane-7-one **396730-74-8P** **396730-85-1P** **396730-93-1P**, trans-6-Benzoyl-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **396731-02-5P** **396731-07-0P** **396731-12-7P**, trans-7-Oxo-6-(phenylmethoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(β-lactamases inhibitor; preparation of azabicycles as inhibitors of β-lactamases)

RN 396730-16-8 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 396730-24-8 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-[1-(phenylmethyl)-1H-tetrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 396730-27-1 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 396730-74-8 CAPLUS
CN Phosphonium, triphenyl-1-propenyl-, salt with rel-2-(phenylmethyl) (1R,2S,5R)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 396730-73-7
CMF C14 H15 N2 O7 S

Relative stereochemistry.



CM 2

CRN 76875-25-7
CMF C21 H20 P



RN 396730-85-1 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 6-benzoyl-7-oxo-, (4-nitrophenyl)methyl ester, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396730-93-1 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 6-benzoyl-7-oxo-,

(1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396731-02-5 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 6-benzoyl-7-oxo-, phenylmethyl ester, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396731-07-0 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 7-oxo-6-(phenylmethoxy)-, 2-propenyl ester, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396731-12-7 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 7-oxo-6-(phenylmethoxy)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **396730-18-0P**, 6-Benzoyl-1,6-diazabicyclo[3.2.1]octane-7-one
396730-20-4P, 7-Oxo-1,6-diazabicyclo[3.2.1]octane-6-acetic acid
396730-23-7P, 7-Oxo-N-phenyl-1,6-diazabicyclo[3.2.1]octane-6-carboxamide **396730-25-9P**, 6-(1H-Tetrazol-5-yl)-1,6-diazabicyclo[3.2.1]octane-7-one **396730-26-0P**, 6-Acetyl-1,6-diazabicyclo[3.2.1]octane-7-one **396730-32-8P**, 6-(Acetyloxy)-1,6-diazabicyclo[3.2.1]octane-7-one **396730-35-1P**, 6-(1-Oxopropoxy)-1,6-diazabicyclo[3.2.1]octane-7-one **396730-36-2P**, 6-[[(4-Methylphenyl)sulfonyl]oxy]-1,6-diazabicyclo[3.2.1]octane-7-one **396730-39-5P**, 6-[(Methylsulfonyl)oxy]-1,6-diazabicyclo[3.2.1]octane-7-one **396730-42-0P**, 6-[[(4-Nitrophenyl)sulfonyl]oxy]-1,6-diazabicyclo[3.2.1]octane-7-one **396730-45-3P**, 6-[[(4-Methylphenyl)sulfonyl]amino]-1,6-diazabicyclo[3.2.1]octane-7-one **396730-50-0P**, 6-[(4-Methylphenyl)sulfonyl]-1,6-diazabicyclo[3.2.1]octane-7-one **396730-80-6P**, Phenylmethyl trans-7-Oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxylate sodium salt **396730-81-7P** **396730-82-8P** **396730-83-9P** **396730-95-3P**, trans-6-Benzoyl-7-oxo-N-(phenylmethyl)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **396730-98-6P** **396731-00-3P** **396731-04-7P**, Phenylmethyl 6-benzoyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-ene-2-carboxylate **396731-06-9P**, 6-Benzoyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-ene-2-carboxylic acid **396731-13-8P** **396731-14-9P** **396731-15-0P** **396731-19-4P** **396731-20-7P** **396731-21-8P** **396731-22-9P** **396731-23-0P** **396731-24-1P** **396731-25-2P** **396731-26-3P** **396731-27-4P** **396731-28-5P** **396731-29-6P** **396731-30-9P** **396731-31-0P** **396731-32-1P** **396731-33-2P** **396731-34-3P** **396731-35-4P** **396731-36-5P** **396731-37-6P** **396731-38-7P** **396731-39-8P**, Sodium salt of 3-methoxy-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-3-en-7-one **396731-55-8P**, Sodium salt of 6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-7-one **396731-63-8P** **396731-64-9P** **396731-65-0P** **396731-66-1P** **396731-67-2P** **573718-04-4P**, 6-Benzoyl-N-[methyl(phenylmethyl)]-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **573718-05-5P**, 6-Benzoyl-2-(hydroxymethyl)-1,6-diazabicyclo[3.2.1]octane-7-one **573718-06-6P** **573718-08-8P** **573718-09-9P** **573718-10-2P** **573718-11-3P** **573718-12-4P** **573718-13-5P** **573718-14-6P** **573718-15-7P** **573718-16-8P** **573718-17-9P** **573718-18-0P** **573718-19-1P** **573718-20-4P** **573718-21-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(β-lactamases inhibitor; preparation of azabicycles as inhibitors of

β-lactamases)

RN 396730-18-0 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-benzoyl- (9CI) (CA INDEX NAME)



RN 396730-20-4 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-6-acetic acid, 7-oxo- (9CI) (CA INDEX NAME)



RN 396730-23-7 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-6-carboxamide, 7-oxo-N-phenyl- (9CI) (CA INDEX NAME)



RN 396730-25-9 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-(1H-tetrazol-5-yl)- (9CI) (CA INDEX NAME)



RN 396730-26-0 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-acetyl- (9CI) (CA INDEX NAME)



RN 396730-32-8 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-(acetyloxy)- (9CI) (CA INDEX NAME)



RN 396730-35-1 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-(1-oxopropoxy)- (9CI) (CA INDEX NAME)



RN 396730-36-2 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-[[(4-methylphenyl)sulfonyl]oxy]- (9CI) (CA INDEX NAME)



RN 396730-39-5 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-[(methylsulfonyl)oxy]- (9CI) (CA INDEX NAME)



RN 396730-42-0 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-[[(4-nitrophenyl)sulfonyl]oxy]- (9CI) (CA INDEX NAME)



RN 396730-45-3 CAPLUS
CN Benzenesulfonamide, 4-methyl-N-(7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl)- (9CI) (CA INDEX NAME)



RN 396730-50-0 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 396730-80-6 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 7-oxo-6-(sulfooxy)-, 2-(phenylmethyl) ester, sodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396730-81-7 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 7-oxo-6-[(phenylsulfonyl)oxy]-, phenylmethyl ester, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396730-82-8 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 7-oxo-6-[(2-thienylsulfonyl)oxy]-, phenylmethyl ester, (1R,2S,5R)-rel- (9CI) (CA

INDEX NAME)

Relative stereochemistry.



RN 396730-83-9 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 6-(carboxymethoxy)-7-oxo-, 2-(phenylmethyl) ester, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396730-95-3 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 6-benzoyl-7-oxo-N-(phenylmethyl)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396730-98-6 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 6-acetyl-7-oxo-, (4-nitrophenyl)methyl ester, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396731-00-3 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2,6-dicarboxylic acid, 7-oxo-, 2-[(4-nitrophenyl)methyl] 6-(2-propenyl) ester, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396731-04-7 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]oct-2-ene-2-carboxylic acid, 6-benzoyl-7-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 396731-06-9 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]oct-2-ene-2-carboxylic acid, 6-benzoyl-7-oxo- (9CI) (CA INDEX NAME)



RN 396731-13-8 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 7-oxo-6-(phenylmethoxy)-, (1R,2S,5R)-rel-, compd. with cyclohexanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 396731-12-7
CMF C14 H16 N2 O4

Relative stereochemistry.



CM 2

CRN 108-91-8
CMF C6 H13 N



RN 396731-14-9 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396731-15-0 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, (1R,2S,5R)-rel-, compd. with pyridine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 396731-14-9
CMF C7 H11 N3 O6 S

Relative stereochemistry.



CM 2

CRN 110-86-1
CMF C5 H5 N

RN 396731-19-4 CAPLUS
CN 1-Butanaminium, N,N,N-tributyl-, salt with rel-(1R,2S,5R)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 396731-18-3
CMF C7 H10 N3 O6 S

Relative stereochemistry.



CM 2

CRN 10549-76-5
CMF C16 H36 N



RN 396731-20-7 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-21-8 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 7-oxo-N-(phenylmethyl)-6-(sulfooxy)-, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-22-9 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 7-oxo-N-(2-pyridinylmethyl)-6-(sulfooxy)-, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-23-0 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 7-oxo-N-[2-(3-pyridinyl)ethyl]-6-(sulfooxy)-, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-24-1 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 7-oxo-N-[2-(4-pyridinyl)ethyl]-6-(sulfooxy)-, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-25-2 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 7-oxo-N-[2-(2-pyridinyl)ethyl]-6-(sulfooxy)-, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-26-3 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, N-[3-(aminocarbonyl)phenyl]-7-oxo-6-(sulfooxy)-, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-27-4 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, N-[4-(dimethylamino)phenyl]-7-oxo-6-(sulfooxy)-, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-28-5 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, N-[3-(dimethylamino)phenyl]-7-oxo-6-(sulfooxy)-, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-29-6 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 7-oxo-N-(4-pyridinylmethyl)-6-(sulfooxy)-, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-30-9 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 7-oxo-N-(3-pyridinylmethyl)-6-(sulfooxy)-, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-31-0 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, N-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-7-oxo-6-(sulfooxy)-, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-32-1 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, N-(2-amino-2-oxoethyl)-7-oxo-6-(sulfooxy)-, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-33-2 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, N-[3-[(aminocarbonyl)amino]phenyl]-7-oxo-6-(sulfooxy)-, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-34-3 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, N-(2-amino-2-oxo-1-phenylethyl)-7-oxo-6-(sulfooxy)-, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-35-4 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 7-oxo-6-(sulfooxy)-, 2-(2-amino-2-oxoethyl) ester, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-36-5 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 7-oxo-6-(sulfooxy)-, 2-[2-(4-pyridinyl)ethyl] ester, sodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-37-6 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 7-oxo-6-(sulfooxy)-, 2-[2-(2-pyridinyl)ethyl] ester, sodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-38-7 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 7-oxo-6-(sulfooxy)-, 2-[2-(3-pyridinyl)ethyl] ester, sodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-39-8 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]oct-3-en-7-one, 3-methoxy-6-(sulfooxy)-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 396731-55-8 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-(sulfooxy)-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 396731-63-8 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 7-oxo-N-(phenylmethyl)-6-(sulfooxy)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396731-64-9 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 7-oxo-N-(4-pyridinylmethyl)-6-(sulfooxy)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396731-65-0 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 7-oxo-N-(3-pyridinylmethyl)-6-(sulfooxy)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396731-66-1 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, N-(2-amino-2-oxoethyl)-7-oxo-6-(sulfooxy)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396731-67-2 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 7-oxo-6-(sulfooxy)-, 2-(phenylmethyl) ester, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 573718-04-4 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 6-benzoyl-N-methyl-7-oxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 573718-05-5 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-benzoyl-2-(hydroxymethyl)- (9CI) (CA INDEX NAME)



RN 573718-06-6 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]oct-3-en-7-one, 6-(sulfooxy)-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 573718-08-8 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 7-oxo-N-[2-(3-pyridinyl)ethyl]-6-(sulfooxy)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 573718-09-9 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 7-oxo-N-[2-(4-pyridinyl)ethyl]-6-(sulfooxy)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 573718-10-2 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 7-oxo-N-[2-(2-pyridinyl)ethyl]-6-(sulfooxy)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 573718-11-3 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, N-[3-(aminocarbonyl)phenyl]-7-oxo-6-(sulfooxy)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 573718-12-4 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, N-[4-(dimethylamino)phenyl]-7-oxo-6-(sulfooxy)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 573718-13-5 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, N-[3-(dimethylamino)phenyl]-7-oxo-6-(sulfooxy)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 573718-14-6 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, N-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-7-oxo-6-(sulfooxy)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 573718-15-7 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, N-[3-[(aminocarbonyl)amino]phenyl]-7-oxo-6-(sulfooxy)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 573718-16-8 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, N-(2-amino-2-oxo-1-phenylethyl)-7-oxo-6-(sulfooxy)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 573718-17-9 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 7-oxo-6-(sulfooxy)-, 2-(2-amino-2-oxoethyl) ester, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 573718-18-0 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 7-oxo-6-(sulfooxy)-, 2-[2-(4-pyridinyl)ethyl] ester, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 573718-19-1 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 7-oxo-6-(sulfooxy)-,

2-[2-(2-pyridinyl)ethyl] ester, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 573718-20-4 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]oct-3-en-7-one, 6-(sulfooxy)- (9CI) (CA INDEX NAME)



RN 573718-21-5 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]oct-3-en-7-one, 3-methoxy-6-(sulfooxy)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:964356 CAPLUS
DOCUMENT NUMBER: 138:39303
TITLE: Preparation of fused-ring diazepines, method of preparation and use as anti-bacterial agents
INVENTOR(S): Aszodi, Joseph; Lampilas, Maxime; Musicki, Branislav; Rowlands, David Alan; Collette, Pascal
PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr.
SOURCE: PCT Int. Appl., 224 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100860	A2	20021219	WO 2002-FR1877	20020604
WO 2002100860	A3	20031120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2825705	A1	20021213	FR 2001-7520	20010608
FR 2825705	B1	20050520		
CA 2449830	AA	20021219	CA 2002-2449830	20020604
EP 1399444	A2	20040324	EP 2002-778894	20020604
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005518333	T2	20050623	JP 2003-503627	20020604
US 2005245505	A1	20051103	US 2004-480019	20040414

PRIORITY APPLN. INFO.: FR 2001-7520 A 20010608
WO 2002-FR1877 W 20020604

OTHER SOURCE(S): MARPAT 138:39303
GI



I

AB The invention concerns novel heterocyclic compds. (shown as I; variables defined below; e.g. 3-benzoyl-1,3,4,5-tetrahydro-1,4-methano-2H-1,3-benzodiazepin-2-one), and their addition salts with a base or an acid. The invention also concerns a method for preparing I, and their use as medicines, in particular as antibacterial agents. For I: (a) R1 = H, COOH, CN, COOR, (CH2)n'R5, CONR6, R7 or C(:NR6)NHR7; R = alkyl containing 1-6 atoms of C,

optionally substituted by pyridyl, a -CH2-alkenyl radical containing 3-9 atoms of C, (poly)alkoxyalkyl containing 1-4 atoms of O and 3-10 atoms of C, aryl with 6-10 atoms of C or aralkyl containing 7-11 atoms of C, the nucleus of the aryl or aralkyl being optionally substituted by OH, NH2, NO2, alkyl containing 1-6 atoms of C, alkoxy containing 1-6 atoms of C or by ≥1 atoms of halogen. R5 = COOH, CN, OH, NH2, CONR6R7, CO2R, OR, OCOH, OCOR, OCO2R, OCONHR, OCONH2, OSO2R, NHR, NHCOR, NHCOH, NHSO2R, NH-COOR, NH-CO-NHR, NH-CO-NH2 or N3; R6 and R7, same or different, = H, alkyl containing 1-6 atoms of C, aryl containing 6-10 atoms of C and aralkyl containing 7-11 atoms of C and alkyl containing 1-6 atoms of C substituted by pyridyl; n' = 1 or 2, R3 and R4 together form a Ph or a heterocycle with aromatic character with 5 or 6 vertexes containing 1-4 heteroatoms = N, O and S, and optionally substituted by ≥1 groups R', R' being = H and alkyl containing 1-6 atoms of C optionally substituted by ≥1 radicals hydroxy, oxo, halogen, or cyano or by a radical nitro, alkenyl containing 2-6 atoms of C, halo, amino, OH, protected OH, -OR, -NHCOH, - NHCOR, NHCOOR, COOH, COOR, -CPh3 and -CH2CH2S(O)mR and m = 0, 1 or 2;. (b) R4 = H or (CH2)n'1R5, n'1 = 0, 1 or 2, and R1 and R3 together form a Ph or a heterocycle optionally substituted. In the 2 cases (a) and (b) R2 = H, halo and R, S(O)mR, OR, NHCOR, NHCOOR and NHSO2R; X = divalent -C(O)-B- bound to N by C atom; B = divalent -O-(CH2)n''- bound to carbonyl by O, -NR8-(CH2)n''- or -NR8-O- bound to carbonyl by N; n'' = 0 or 1 and R8 = H, OH, R, OR, Y, OY, Y1, OY1, Y2, OY2, Y3, O-CH2-CH2-S(O)m-R, SiRaRbRc and OSiRaRbRc, Ra, Rb and Rc representing individually linear or branched alkyl containing 1-6 atoms of C or aryl containing 6-10 atoms of C; Y = COH, COR, COOR, CONH2, CONHR, CONHOH, CONHSO2R, CH2COOH, CH2COOR, CH2CONHOH, CH2CONHCN, CH2tetrazole, protected CH2tetrazole, CH2SO3H, CH2SO2R, CH2PO(OR)2, CH2PO(OR)(OH), CH2PO(R)(OH) and CH2PO(OH)2. Y1 = SO2R, SO2NHCOH, SO2NHCOR, SO2NHCOOR, SO2NHCONHR, SO2NHCONH2 and SO3H; Y2 = PO(OH)2, PO(OR)2, PO(OH)(OR) and PO(OH)(R); Y3 = tetrazole, tetrazole substituted by radical R, squarate, NH or NR tetrazole, NH or NR tetrazole substituted by radical R, NHSO2R and NRSO2R; n = 1 or 2. Sixty-eight example prepns. are included. For example, 3-benzoyl-1,3,4,5-tetrahydro-1,4-methano-2H-1,3-benzodiazepin-2-one was prepared in 2 steps comprising treatment of N-(1,2,3,4-tetrahydro-3-quinolinyl)benzamide in CH2Cl2 with Et3N followed by diphosgene in the 1st step (76 %) followed by addition of LiN(SiMe3)2 in THF to the intermediate (63 %). Eleven I were tested for antibacterial activity against 3 gram-pos. and 3 gram-neg. bacteria and the results are tabulated in ranges.

IT **478623-75-5P 478623-99-3P 478626-16-3P**
478626-79-8P 478627-42-8P 478627-67-7P
478627-73-5P 478627-86-0P 478627-91-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of fused-ring diazepines, method of preparation and use as anti-bacterial agents)

RN 478623-75-5 CAPLUS

CN Phosphonium, triphenyl-1-propenyl-, salt with 1,3,4,5-tetrahydro-3-oxo-4-(sulfooxy)-2,5-methano-2H-2,4-benzodiazepine-1-carboxylic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478623-74-4
CMF C11 H9 N2 O7 S



CM 2

CRN 76875-25-7
CMF C21 H20 P



RN 478623-99-3 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-3-oxo-4-(phenylmethoxy)-, methyl ester, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478626-16-3 CAPLUS
CN 6H-4,7-Methano-1,2,3-triazolo[4,5-e][1,3]diazepin-6-one, 2,4,5,8-tetrahydro-5-(phenylmethoxy)-2-[2-(phenylthio)ethyl]- (9CI) (CA INDEX NAME)



RN 478626-79-8 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 1,3,4,5-tetrahydro-7-[(2-methoxyethoxy)methoxy]-3-oxo-4-(sulfooxy)-, monosodium salt, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 478627-42-8 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-3-oxo-6-(phenylmethoxy)-4-(sulfooxy)-, 1-methyl ester, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478627-67-7 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepin-3(1H)-one, 4,5-dihydro-1-[(phenylmethoxy)methyl]-4-(sulfooxy)-, sodium salt, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 478627-73-5 CAPLUS
CN Carbamic acid, [[(4R,7R,8R)-4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepin-8-yl]methyl]-, C-(1,1-dimethylethyl) ester, monosodium salt, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 478627-86-0 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepin-6(5H)-one, 8-(aminomethyl)-4,8-dihydro-5-(sulfooxy)-, (4R,7R,8R)-rel-, monosodium salt, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 478627-85-9
CMF C9 H11 N3 O5 S2

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 478627-91-7 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-, methyl ester, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **478623-88-0P 478623-89-1P 478624-03-2P**
478624-08-7P 478624-13-4P 478624-16-7P
478624-19-0P 478624-22-5P 478624-25-8P
478624-26-9P 478624-30-5P 478624-32-7P
478624-42-9P 478624-50-9P 478624-61-2P
478624-66-7P 478624-77-0P 478624-87-2P
478625-00-2P 478625-17-1P 478625-29-5P
478625-34-2P 478625-37-5P 478625-43-3P
478625-60-4P 478625-79-5P 478625-84-2P
478625-93-3P 478625-98-8P 478626-48-1P
478626-49-2P 478626-51-6P 478626-61-8P

478626-66-3P 478626-67-4P 478626-77-6P
478626-88-9P 478626-89-0P 478627-01-9P
478627-29-1P 478627-41-7P, Ethyl 1,2,3,4-tetrahydro-3-oxo-2-(phenylmethoxy)-9-(2-propenyloxy)-1,4-methano-4H-2,4-benzodiazepine-5-carboxylate **478627-49-5P 478627-50-8P**
478627-52-0P 478627-54-2P 478627-57-5P
478627-70-2P 478627-71-3P 478627-87-1P
478627-88-2P 478628-03-4P 478628-08-9P
478628-10-3P 478628-19-2P 478628-31-8P
478628-36-3P 478628-45-4P 478628-49-8P
478628-54-5P 478628-57-8P 478628-59-0P
478628-66-9P 478628-69-2P 478628-74-9P
478628-82-9P 478686-31-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of fused-ring diazepines, method of preparation and
use as anti-bacterial agents)

RN 478623-88-0 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-3-oxo-4-(sulfooxy)-, 1-methyl ester, sodium salt, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 478623-89-1 CAPLUS
CN 6H-4,7-Methanopyrazolo[3,4-e][1,3]diazepin-6-one, 1,4,5,8-tetrahydro-1-methyl-5-(sulfooxy)-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 478624-03-2 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 1,3,4,5-tetrahydro-3-oxo-N-(phenylmethyl)-4-(sulfooxy)-, monosodium salt, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 478624-08-7 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 1,3,4,5-tetrahydro-3-oxo-N-(4-pyridinylmethyl)-4-(sulfooxy)-, monosodium salt, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 478624-13-4 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 1,3,4,5-tetrahydro-3-oxo-4-(sulfooxy)-, monosodium salt, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 478624-16-7 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 1,3,4,5-tetrahydro-4-hydroxy-3-oxo-, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478624-19-0 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-3-oxo-4-(sulfooxy)-, disodium salt, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 Na

RN 478624-22-5 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-3-oxo-4-(phosphonooxy)-, 1-methyl ester, disodium salt, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 Na

RN 478624-25-8 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-4-[[hydroxy(phenylmethoxy)phosphinyl]oxy]-3-oxo-, methyl ester, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478624-26-9 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 1,3,4,5-tetrahydro-N-methyl-3-oxo-4-(sulfooxy)-, monosodium salt, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 478624-30-5 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 4-(carboxymethoxy)-1,3,4,5-tetrahydro-3-oxo-, 1-methyl ester, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478624-32-7 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-3-oxo-4-sulfo-, 1-methyl ester, sodium salt, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 478624-42-9 CAPLUS
CN 6H-4,7-Methanopyrazolo[3,4-e][1,3]diazepin-6-one, 1,4,5,8-tetrahydro-1-propyl-5-(sulfooxy)-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 478624-50-9 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-1-methyl-6-oxo-5-(sulfooxy)-, 8-methyl ester, sodium salt, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 478624-61-2 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxamide, 4,5,6,8-tetrahydro-1-methyl-6-oxo-5-(sulfooxy)-, monosodium salt, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 478624-66-7 CAPLUS
CN Carbamic acid, [4,6,7,8-tetrahydro-6-oxo-7-(sulfooxy)-5,8-methano-5H-thiazolo[4,5-e][1,3]diazepin-2-yl]-, C-(phenylmethyl) ester, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 478624-77-0 CAPLUS
CN 4,7-Methano-7H-oxazolo[4,5-e][1,3]diazepin-6(5H)-one, 4,8-dihydro-2-methyl-5-(sulfooxy)-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 478624-87-2 CAPLUS
CN 6H-4,7-Methanoimidazo[4,5-e][1,3]diazepin-6-one, 1,4,5,8-tetrahydro-1-propyl-5-(sulfooxy)-, compd. with pyridine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478624-86-1
CMF C10 H14 N4 O5 S



CM 2

CRN 110-86-1
CMF C5 H5 N



RN 478625-00-2 CAPLUS
CN 2,5-Methano-2H-pyrido[3,4-e][1,3]diazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-6,8-dimethoxy-3-oxo-4-(sulfooxy)-, 1-ethyl ester, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 478625-17-1 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-6-oxo-5-(2-propenyloxy)-, methyl ester, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478625-29-5 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide, 4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-, monosodium salt, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 478625-34-2 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-, 8-methyl ester, sodium salt, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 478625-37-5 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide, 4,5,6,8-tetrahydro-6-oxo-N-(phenylmethyl)-5-(sulfooxy)-, monosodium salt, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 478625-43-3 CAPLUS
CN 4,7-Methano-7H-furo[2,3-e][1,3]diazepin-6(5H)-one, 4,8-dihydro-5-(sulfooxy)-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 478625-60-4 CAPLUS
CN 4,7-Methano-7H-furo[2,3-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-6-oxo-5-(2-propenyloxy)-, methyl ester, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478625-79-5 CAPLUS
CN 4,7-Methano-7H-furo[2,3-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-, 8-methyl ester, sodium salt,

(4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 478625-84-2 CAPLUS
CN 4,7-Methano-7H-furo[2,3-e][1,3]diazepine-8-carboxamide, 4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-, monosodium salt, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 478625-93-3 CAPLUS
CN 2,5-Methano-2H-pyrido[3,4-e][1,3]diazepine-1-carboxamide, 1,3,4,5-tetrahydro-4-hydroxy-6,8-dimethoxy-3-oxo- (9CI) (CA INDEX NAME)



RN 478625-98-8 CAPLUS
CN 5H-1,4-Methano-3H-furo[3,4-e][1,3]diazepin-3(2H)-one, 2-(sulfooxy)-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 478626-48-1 CAPLUS
CN 6H-4,7-Methano-1,2,3-triazolo[4,5-e][1,3]diazepin-6-one, 2,4,5,8-tetrahydro-2-[2-(phenylsulfonyl)ethyl]-5-(sulfooxy)-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 478626-49-2 CAPLUS
CN 6H-4,7-Methano-1,2,3-triazolo[4,5-e][1,3]diazepin-6-one, 2,4,5,8-tetrahydro-2-[(phenylsulfonyl)ethyl]-5-(sulfooxy)-, compd. with N,N-diethylethanamine (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 478626-46-9
CMF C14 H15 N5 O7 S2



CM 2

CRN 121-44-8
CMF C6 H15 N



RN 478626-51-6 CAPLUS
CN 6H-4,7-Methano-1,2,3-triazolo[4,5-e][1,3]diazepin-6-one, 2,4,5,8-tetrahydro-2-methyl-5-(sulfooxy)-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 478626-61-8 CAPLUS
CN 6H-4,7-Methano-1,2,3-triazolo[4,5-e][1,3]diazepin-6-one, 1,4,5,8-tetrahydro-1-methyl-5-(sulfooxy)-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 478626-66-3 CAPLUS
CN 6H-4,7-Methano-1,2,3-triazolo[4,5-e][1,3]diazepin-6-one, 3,4,5,8-tetrahydro-3-methyl-5-(sulfooxy)-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 478626-67-4 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-3-oxo-4-(phenylmethoxy)-7-(2-propenyloxy)-, ethyl ester, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478626-77-6 CAPLUS

CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-3-oxo-7-propoxy-4-(sulfooxy)-, 1-ethyl ester, sodium salt, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 478626-88-9 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 1,3,4,5-tetrahydro-7-hydroxy-3-oxo-4-(sulfooxy)-, (1R,2S,5S)-rel-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478626-87-8
CMF C11 H11 N3 O7 S

Relative stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



RN 478626-89-0 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 8-(acetylamino)-1,3,4,5-tetrahydro-7-hydroxy-3-oxo-4-(sulfooxy)-, monosodium salt, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 478627-01-9 CAPLUS
CN 1H-4,7-Methanoimidazo[4,5-e][1,3]diazepine-1-carboxylic acid, 4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-, 1-(1,1-dimethylethyl) ester, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 478627-29-1 CAPLUS
CN 6H-4,7-Methanoimidazo[4,5-e][1,3]diazepin-6-one, 1,4,5,8-tetrahydro-5-(sulfooxy)-, monosodium salt, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 478627-28-0
CMF C7 H8 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 478627-41-7 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 3,4,5,5a-tetrahydro-3-oxo-4-(phenylmethoxy)-6-(2-propenyloxy)-, ethyl ester (9CI) (CA INDEX NAME)



RN 478627-49-5 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-6-hydroxy-3-oxo-4-(sulfooxy)-, 1-methyl ester, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478627-50-8 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-3-oxo-6-propoxy-4-(sulfooxy)-, 1-ethyl ester, sodium salt, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 478627-52-0 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1-fluoro-1,3,4,5-tetrahydro-3-oxo-4-(sulfooxy)-, 1-methyl ester, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 478627-54-2 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-1-(methylthio)-3-oxo-4-(sulfooxy)-, 1-methyl ester, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 478627-57-5 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-8-methyl-6-oxo-5-(sulfooxy)-, 8-methyl ester, (4R,7R,8R)-rel-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478627-56-4
CMF C11 H12 N2 O7 S2

Relative stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



RN 478627-70-2 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepin-3(1H)-one, 4,5-dihydro-1-(hydroxymethyl)-4-(sulfooxy)-, monosodium salt, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 478627-71-3 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepin-3(1H)-one, 1-[[(aminocarbonyl)oxy]methyl]-4,5-dihydro-4-(sulfooxy)-, monosodium salt, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 478627-87-1 CAPLUS
CN Acetamide, N-[[(4R,7R,8R)-4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepin-8-yl]methyl]-, monosodium salt, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 478627-88-2 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide, 4,5,6,8-tetrahydro-N-methyl-6-oxo-5-(sulfooxy)-, monosodium salt, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 478628-03-4 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 1-ethyl-4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-, 8-methyl ester, (4R,7R,8S)-rel-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478628-02-3
CMF C11 H14 N4 O7 S

Relative stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



RN 478628-08-9 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid,

2-ethyl-2,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-, 8-methyl ester, (4R,7R,8S)-rel-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478628-07-8
CMF C11 H14 N4 O7 S

Relative stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



RN 478628-10-3 CAPLUS
CN Acetamide, N-[4,6,7,8-tetrahydro-6-oxo-7-(sulfooxy)-5,8-methano-5H-thiazolo[4,5-e][1,3]diazepin-2-yl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 478628-19-2 CAPLUS
CN 5,8-Methano-5H-thieno[2,3-e][1,3]diazepin-6(4H)-one, 7,8-dihydro-7-(sulfooxy)-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 478628-31-8 CAPLUS
CN 4,7-Methano-7H-isoxazolo[4,5-e][1,3]diazepin-6(5H)-one, 4,8-dihydro-5-(sulfooxy)-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 478628-36-3 CAPLUS
CN 5,8-Methano-8H-pyrido[2,3-e][1,3]diazepin-7(6H)-one, 5,9-dihydro-6-(sulfooxy)-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 478628-45-4 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 2,5,6,8-tetrahydro-2-methyl-6-oxo-5-(sulfooxy)-, 8-methyl ester, sodium salt, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 478628-49-8 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 2-ethyl-4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-, 8-methyl ester, (4R,7R,8R)-rel-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478628-48-7
CMF C12 H14 N2 O7 S2

Relative stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



RN 478628-54-5 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid,

4,5,6,8-tetrahydro-2-methyl-6-oxo-5-(sulfooxy)-, 8-methyl ester, (4R,7R,8R)-rel-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478628-53-4
CMF C11 H12 N2 O7 S2

Relative stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



RN 478628-57-8 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide, 4,5,6,8-tetrahydro-6-oxo-5-[(phenylsulfonyl)oxy]-, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478628-59-0 CAPLUS
CN Acetamide, N-[5,6,7,9-tetrahydro-7-oxo-6-(sulfooxy)-5,8-methano-8H-pyrimido[4,5-e][1,3]diazepin-2-yl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 478628-66-9 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide, 2-bromo-4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-, (4R,7R,8S)-rel-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478628-65-8
CMF C9 H8 Br N3 O6 S2

Relative stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



RN 478628-69-2 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid,

4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-, 8-methyl ester, (4R,7R,8S)-rel-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478628-68-1
CMF C9 H10 N4 O7 S

Relative stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



RN 478628-74-9 CAPLUS
CN 6H-4,7-Methanopyrazolo[3,4-e][1,3]diazepin-6-one, 1,4,5,8-tetrahydro-5-(sulfooxy)-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 478628-82-9 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 1,3,4,5-tetrahydro-7-hydroxy-3-oxo-4-(sulfooxy)-, monosodium salt, (1R,2S,5S)-rel- (9CI) (CA

INDEX NAME)

Relative stereochemistry.



● Na

RN 478686-31-6 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-8-methyl-6-oxo-5-(sulfooxy)-, 8-methyl ester, (4R,7R,8S)-rel-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478686-30-5
CMF C11 H12 N2 O7 S2

Relative stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



IT **478623-69-7P 478623-71-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of fused-ring diazepines, method of preparation and
use as antibacterial agents)
RN 478623-69-7 CAPLUS
CN 1,4-Methano-1H-1,3-benzodiazepin-2(3H)-one, 3-benzoyl-4,5-dihydro- (9CI) (CA INDEX NAME)



RN 478623-71-1 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepin-3(1H)-one, 4-benzoyl-4,5-dihydro- (9CI) (CA INDEX NAME)



IT **478628-58-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of fused-ring diazepines, method of preparation and use as anti-bacterial agents)
RN 478628-58-9 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide, 4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **478623-87-9P 478623-96-0P 478623-98-2P**
478624-04-3P 478624-05-4P 478624-07-6P
478624-09-8P 478624-10-1P 478624-12-3P
478624-15-6P 478624-17-8P 478624-18-9P
478624-20-3P 478624-21-4P 478624-23-6P
478624-24-7P 478624-27-0P 478624-29-2P
478624-31-6P 478624-38-3P 478624-39-4P
478624-41-8P 478624-48-5P 478624-49-6P
478624-58-7P 478624-60-1P 478624-62-3P
478624-63-4P 478624-65-6P 478624-74-7P
478624-76-9P 478624-83-8P 478624-85-0P
478624-98-5P 478624-99-6P 478625-14-8P
478625-16-0P 478625-30-8P 478625-31-9P
478625-33-1P 478625-36-4P 478625-39-7P
478625-41-1P 478625-55-7P, 5-(2-Propenyloxy)-5,6,7,8-tetrahydro-4,7-methano-4H-furo[2,3-e][1,3]diazepin-6-one
478625-58-0P 478625-82-0P 478625-86-4P
478625-88-6P 478625-91-1P 478625-94-4P
478625-96-6P 478626-12-9P 478626-14-1P
478626-42-5P, 5-(Phenylmethoxy)-2-[2-(phenylsulfonyl)ethyl]-5,6,7,8-tetrahydro-4,7-methano-4H-[1,2,3]triazolo[4,5-e][1,3]diazepin-6(2H)-one **478626-44-7P**, 5-Hydroxy-2-[2-(phenylsulfonyl)ethyl]-5,6,7,8-tetrahydro-4,7-methano-4H-[1,2,3]triazolo[4,5-e][1,3]diazepin-6(2H)-one **478626-47-0P 478626-53-8P**
478626-55-0P, 2-Methyl-5-(phenylmethoxy)-5,6,7,8-tetrahydro-4,7-methano-4H-[1,2,3]triazolo[4,5-e][1,3]diazepin-6(2H)-one
478626-58-3P, 5-Hydroxy-2-methyl-5,6,7,8-tetrahydro-4,7-methano-4H-[1,2,3]triazolo[4,5-e][1,3]diazepin-6(2H)-one **478626-60-7P**
478626-63-0P 478626-65-2P 478626-78-7P
478626-81-2P 478626-82-3P 478626-84-5P
478626-85-6P 478626-86-7P 478626-90-3P
478626-91-4P 478626-93-6P 478626-94-7P
478626-96-9P 478626-97-0P 478626-99-2P
478627-00-8P 478627-23-5P 478627-24-6P
478627-25-7P 478627-26-8P 478627-27-9P
478627-47-3P 478627-48-4P 478627-51-9P
478627-53-1P 478627-55-3P 478627-63-3P
478627-64-4P 478627-65-5P 478627-66-6P
478627-68-8P 478627-69-9P 478627-72-4P
478627-78-0P 478627-79-1P 478627-80-4P
478627-81-5P 478627-82-6P 478627-83-7P
478627-84-8P 478627-89-3P 478627-90-6P
478628-04-5P 478628-05-6P 478628-06-7P
478628-09-0P 478628-15-8P 478628-16-9P
478628-18-1P 478628-30-7P, 7,8-Dihydro-7-(2-propenyloxy)-

5,8-methano-5H-thieno[3,2-e][1,3]diazepin-6(4H)-one **478628-35-2P** **478628-44-3P**, 5,9-Dihydro-6-(2-propenyloxy)-5,8-methano-8H-pyrido[2,3-e][1,3]diazepin-7(6H)-one **478628-46-5P** **478628-47-6P** **478628-50-1P** **478628-51-2P** **478628-52-3P** **478628-55-6P** **478628-56-7P** **478628-64-7P** **478628-72-7P** **478628-73-8P** **478628-75-0P** **478628-76-1P** **478628-77-2P** **478628-78-3P** **478628-79-4P** **478628-80-7P** **478628-81-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of fused-ring diazepines, method of preparation and use as anti-bacterial agents)

RN 478623-87-9 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-3-oxo-4-(2-propenyloxy)-, methyl ester, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478623-96-0 CAPLUS
CN 6H-4,7-Methanopyrazolo[3,4-e][1,3]diazepin-6-one, 1,4,5,8-tetrahydro-1-methyl-5-(1-propenyloxy)- (9CI) (CA INDEX NAME)



RN 478623-98-2 CAPLUS
CN Phosphonium, triphenyl-1-propenyl-, salt with 1,4,5,8-tetrahydro-1-methyl-5-(sulfooxy)-6H-4,7-methanopyrazolo[3,4-e][1,3]diazepin-6-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478623-97-1

CMF C8 H9 N4 O5 S



CM 2

CRN 76875-25-7
CMF C21 H20 P

$Ph_3{}^+P-CH=CH-Me$

RN 478624-04-3 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-3-oxo-4-(2-propenyloxy)-, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478624-05-4 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 1,3,4,5-tetrahydro-3-oxo-N-(phenylmethyl)-4-(2-propenyloxy)-, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478624-07-6 CAPLUS
CN Phosphonium, triphenyl-1-propenyl-, salt with rel-(1R,2S,5S)-1,3,4,5-tetrahydro-3-oxo-N-(phenylmethyl)-4-(sulfooxy)-2,5-methano-2H-2,4-benzodiazepine-1-carboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478624-06-5
CMF C18 H16 N3 O6 S

Relative stereochemistry.



CM 2

CRN 76875-25-7
CMF C21 H20 P



RN 478624-09-8 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 1,3,4,5-tetrahydro-3-oxo-4-(2-propenyloxy)-N-(4-pyridinylmethyl)-, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478624-10-1 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 1,3,4,5-tetrahydro-4-hydroxy-3-oxo-N-(4-pyridinylmethyl)-, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478624-12-3 CAPLUS
CN Phosphonium, triphenyl-1-propenyl-, salt with rel-(1R,2S,5S)-1,3,4,5-tetrahydro-3-oxo-N-(4-pyridinylmethyl)-4-(sulfooxy)-2,5-methano-2H-2,4-benzodiazepine-1-carboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478624-11-2
CMF C17 H15 N4 O6 S

Relative stereochemistry.



CM 2

CRN 76875-25-7
CMF C21 H20 P

$Ph_3{}^+P-CH=CH-Me$

RN 478624-15-6 CAPLUS
CN Phosphonium, triphenyl-1-propenyl-, salt with rel-(1R,2S,5S)-1,3,4,5-tetrahydro-3-oxo-4-(sulfooxy)-2,5-methano-2H-2,4-benzodiazepine-1-carboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478624-14-5
CMF C11 H10 N3 O6 S

Relative stereochemistry.



CM 2

CRN 76875-25-7
CMF C21 H20 P

$Ph_3{}^+P-CH=CH-Me$

RN 478624-17-8 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-3-oxo-4-(phenylmethoxy)-, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478624-18-9 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 1,3,4,5-tetrahydro-3-oxo-4-(phenylmethoxy)-, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478624-20-3 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-4-hydroxy-3-oxo-, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478624-21-4 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-3-oxo-4-(sulfooxy)-, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478624-23-6 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-4-hydroxy-3-oxo-, methyl ester, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478624-24-7 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 4-[[bis(phenylmethoxy)phosphinyl]oxy]-1,3,4,5-tetrahydro-3-oxo-, methyl ester, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478624-27-0 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 1,3,4,5-tetrahydro-N-methyl-3-oxo-4-(2-propenyloxy)-, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478624-29-2 CAPLUS
CN Phosphonium, triphenyl-1-propenyl-, salt with rel-(1R,2S,5S)-1,3,4,5-tetrahydro-N-methyl-3-oxo-4-(sulfooxy)-2,5-methano-2H-2,4-benzodiazepine-1-carboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478624-28-1
CMF C12 H12 N3 O6 S

Relative stereochemistry.



CM 2

CRN 76875-25-7
CMF C21 H20 P

$Ph_3{}^{+}P-CH=CH-Me$

RN 478624-31-6 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-3-oxo-4-[2-oxo-2-(phenylmethoxy)ethoxy]-, methyl ester, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478624-38-3 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1,4(3H)-dicarboxylic acid, 1,5-dihydro-3-oxo-, 1-methyl 4-(phenylmethyl) ester, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478624-39-4 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-3-oxo-, methyl ester, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478624-41-8 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-3-oxo-4-sulfo-, 1-methyl ester, (1R,2S,5S)-rel-, compd. with pyridine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478624-40-7
CMF C12 H12 N2 O6 S

Relative stereochemistry.



CM 2

CRN 110-86-1
CMF C5 H5 N

RN 478624-48-5 CAPLUS
CN 6H-4,7-Methanopyrazolo[3,4-e][1,3]diazepin-6-one, 1,4,5,8-tetrahydro-5-(phenylmethoxy)-1-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 478624-49-6 CAPLUS
CN 6H-4,7-Methanopyrazolo[3,4-e][1,3]diazepin-6-one, 1,4,5,8-tetrahydro-5-hydroxy-1-propyl- (9CI) (CA INDEX NAME)



RN 478624-58-7 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-1-methyl-6-oxo-5-(2-propenyloxy)-, methyl ester, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478624-60-1 CAPLUS
CN Phosphonium, triphenyl-1-propenyl-, salt with rel-8-methyl (4R,7R,8R)-4,5,6,8-tetrahydro-1-methyl-6-oxo-5-(sulfooxy)-1H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478624-59-8
CMF C10 H11 N4 O7 S

Relative stereochemistry.



CM 2

CRN 76875-25-7
CMF C21 H20 P

$Ph_3{}^{+}P-CH=CH-Me$

RN 478624-62-3 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-1-methyl-6-oxo-5-(2-propenyloxy)-, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478624-63-4 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxamide, 4,5,6,8-tetrahydro-1-methyl-6-oxo-5-(2-propenyloxy)-, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478624-65-6 CAPLUS
CN Phosphonium, triphenyl-1-propenyl-, salt with rel-(4R,7R,8R)-4,5,6,8-tetrahydro-1-methyl-6-oxo-5-(sulfooxy)-1H-4,7-methanopyrazolo[3,4-e][1,3]diazepine-8-carboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478624-64-5
CMF C9 H10 N5 O6 S

Relative stereochemistry.



CM 2

CRN 76875-25-7
CMF C21 H20 P



RN 478624-74-7 CAPLUS
CN Carbamic acid, [4,6,7,8-tetrahydro-6-oxo-7-(2-propenyloxy)-5,8-methano-5H-thiazolo[4,5-e][1,3]diazepin-2-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 478624-76-9 CAPLUS
CN Phosphonium, triphenyl-1-propenyl-, salt with C-(phenylmethyl) [4,6,7,8-tetrahydro-6-oxo-7-(sulfooxy)-5,8-methano-5H-thiazolo[4,5-e][1,3]diazepin-2-yl]carbamate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478624-75-8
CMF C15 H13 N4 O7 S2



CM 2

CRN 76875-25-7
CMF C21 H20 P



RN 478624-83-8 CAPLUS
CN 4,7-Methano-7H-oxazolo[4,5-e][1,3]diazepin-6(5H)-one, 4,8-dihydro-2-methyl-

5-(2-propenyloxy)- (9CI) (CA INDEX NAME)



RN 478624-85-0 CAPLUS
CN Phosphonium, triphenyl-1-propenyl-, salt with 4,8-dihydro-2-methyl-5-(sulfooxy)-4,7-methano-7H-oxazolo[4,5-e][1,3]diazepin-6(5H)-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478624-84-9
CMF C8 H8 N3 O6 S



CM 2

CRN 76875-25-7
CMF C21 H20 P



RN 478624-98-5 CAPLUS
CN 6H-4,7-Methanoimidazo[4,5-e][1,3]diazepin-6-one, 1,4,5,8-tetrahydro-5-(phenylmethoxy)-1-propyl- (9CI) (CA INDEX NAME)



RN 478624-99-6 CAPLUS
CN 6H-4,7-Methanoimidazo[4,5-e][1,3]diazepin-6-one, 1,4,5,8-tetrahydro-5-hydroxy-1-propyl- (9CI) (CA INDEX NAME)



RN 478625-14-8 CAPLUS
CN 2,5-Methano-2H-pyrido[3,4-e][1,3]diazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-6,8-dimethoxy-3-oxo-4-(2-propenyloxy)-, ethyl ester (9CI) (CA INDEX NAME)



RN 478625-16-0 CAPLUS
CN Phosphonium, triphenyl-1-propenyl-, salt with 1-ethyl 1,3,4,5-tetrahydro-6,8-dimethoxy-3-oxo-4-(sulfooxy)-2,5-methano-2H-pyrido[3,4-e][1,3]diazepine-1-carboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478625-15-9
CMF C14 H16 N3 O9 S



CM 2

CRN 76875-25-7
CMF C21 H20 P

$Ph_3{}^{+}P-CH=\!=CH-Me$

RN 478625-30-8 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-6-oxo-5-(2-propenyloxy)-, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478625-31-9 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide, 4,5,6,8-tetrahydro-6-oxo-5-(2-propenyloxy)-, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478625-33-1 CAPLUS
CN Phosphonium, triphenyl-1-propenyl-, salt with rel-(4R,7R,8S)-4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478625-32-0
CMF C9 H8 N3 O6 S2

Relative stereochemistry.



CM 2

CRN 76875-25-7
CMF C21 H20 P

$Ph_3{}^+P-CH=CH-Me$

RN 478625-36-4 CAPLUS
CN Phosphonium, triphenyl-1-propenyl-, 8-methyl rel-(4R,7R,8S)-4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478625-35-3
CMF C10 H9 N2 O7 S2

Relative stereochemistry.



CM 2

CRN 76875-25-7
CMF C21 H20 P

$Ph_3{}^+P-CH=CH-Me$

RN 478625-39-7 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide, 4,5,6,8-tetrahydro-6-oxo-N-(phenylmethyl)-5-(2-propenyloxy)-, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478625-41-1 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide, 4,5,6,8-tetrahydro-5-hydroxy-6-oxo-N-(phenylmethyl)-, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478625-55-7 CAPLUS
CN 4,7-Methano-7H-furo[2,3-e][1,3]diazepin-6(3aH)-one, 4,5,8,8a-tetrahydro-5-(2-propenyloxy)- (9CI) (CA INDEX NAME)



RN 478625-58-0 CAPLUS
CN Phosphonium, triphenyl-1-propenyl-, salt with 4,8-dihydro-5-(sulfooxy)-4,7-methano-7H-furo[2,3-e][1,3]diazepin-6(5H)-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478625-57-9
CMF C8 H7 N2 O6 S



CM 2

CRN 76875-25-7
CMF C21 H20 P

$Ph_3{}^{+}P-CH=CH-Me$

RN 478625-82-0 CAPLUS
CN Phosphonium, triphenyl-1-propenyl-, salt with rel-8-methyl (4R,7R,8R)-4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-4,7-methano-7H-furo[2,3-e][1,3]diazepine-8-carboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478625-81-9
CMF C10 H9 N2 O8 S

Relative stereochemistry.



CM 2

CRN 76875-25-7
CMF C21 H20 P

$Ph_3{}^{+}P-CH=CH-Me$

RN 478625-86-4 CAPLUS
CN 4,7-Methano-7H-furo[2,3-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-6-oxo-5-(2-propenyloxy)-, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478625-88-6 CAPLUS
CN 4,7-Methano-7H-furo[2,3-e][1,3]diazepine-8-carboxamide, 4,5,6,8-tetrahydro-6-oxo-5-(2-propenyloxy)-, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478625-91-1 CAPLUS
CN Phosphonium, triphenyl-1-propenyl-, salt with rel-(4R,7R,8R)-4,5,6,8-tetrahydro-6-oxo-5-(sulfooxy)-4,7-methano-7H-furo[2,3-e][1,3]diazepine-8-carboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478625-90-0
CMF C9 H8 N3 O7 S

Relative stereochemistry.



CM 2

CRN 76875-25-7
CMF C21 H20 P



RN 478625-94-4 CAPLUS
CN 2,5-Methano-2H-pyrido[3,4-e][1,3]diazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-6,8-dimethoxy-3-oxo-4-(2-propenyloxy)- (9CI) (CA INDEX NAME)



RN 478625-96-6 CAPLUS
CN 2,5-Methano-2H-pyrido[3,4-e][1,3]diazepine-1-carboxamide, 1,3,4,5-tetrahydro-6,8-dimethoxy-3-oxo-4-(2-propenyloxy)- (9CI) (CA INDEX NAME)



RN 478626-12-9 CAPLUS
CN 5H-1,4-Methano-3H-furo[3,4-e][1,3]diazepin-3-one, 1,2-dihydro-2-(2-propenyloxy)- (9CI) (CA INDEX NAME)



RN 478626-14-1 CAPLUS
CN Phosphonium, triphenyl-1-propenyl-, salt with 1,2-dihydro-2-(sulfooxy)-5H-1,4-methano-3H-furo[3,4-e][1,3]diazepin-3-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478626-13-0
CMF C8 H7 N2 O6 S



CM 2

CRN 76875-25-7
CMF C21 H20 P



RN 478626-42-5 CAPLUS
CN 6H-4,7-Methano-1,2,3-triazolo[4,5-e][1,3]diazepin-6-one, 2,4,5,8-tetrahydro-5-(phenylmethoxy)-2-[2-(phenylsulfonyl)ethyl]- (9CI) (CA INDEX NAME)



RN 478626-44-7 CAPLUS
CN 6H-4,7-Methano-1,2,3-triazolo[4,5-e][1,3]diazepin-6-one, 2,4,5,8-tetrahydro-5-hydroxy-2-[2-(phenylsulfonyl)ethyl]- (9CI) (CA INDEX NAME)



RN 478626-47-0 CAPLUS
CN 6H-4,7-Methano-1,2,3-triazolo[4,5-e][1,3]diazepin-6-one, 2,4,5,8-tetrahydro-2-[2-(phenylsulfonyl)ethyl]-5-(sulfooxy)-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478626-46-9
CMF C14 H15 N5 O7 S2



CM 2

CRN 121-44-8

CMF C6 H15 N



RN 478626-53-8 CAPLUS
CN 6H-4,7-Methano-1,2,3-triazolo[4,5-e][1,3]diazepin-6-one,
1,4,5,8-tetrahydro-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 478626-55-0 CAPLUS
CN 6H-4,7-Methano-1,2,3-triazolo[4,5-e][1,3]diazepin-6-one,
2,4,5,8-tetrahydro-2-methyl-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 478626-58-3 CAPLUS
CN 6H-4,7-Methano-1,2,3-triazolo[4,5-e][1,3]diazepin-6-one,
2,4,5,8-tetrahydro-5-hydroxy-2-methyl- (9CI) (CA INDEX NAME)



RN 478626-60-7 CAPLUS
CN 6H-4,7-Methano-1,2,3-triazolo[4,5-e][1,3]diazepin-6-one,
2,4,5,8-tetrahydro-2-methyl-5-(sulfooxy)-, compd. with
N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478626-59-4
CMF C7 H9 N5 O5 S



CM 2

CRN 121-44-8
CMF C6 H15 N



RN 478626-63-0 CAPLUS
CN 6H-4,7-Methano-1,2,3-triazolo[4,5-e][1,3]diazepin-6-one, 1,4,5,8-tetrahydro-1-methyl-5-(sulfooxy)-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478626-62-9
CMF C7 H9 N5 O5 S



CM 2

CRN 121-44-8
CMF C6 H15 N



RN 478626-65-2 CAPLUS
CN 6H-4,7-Methano-1,2,3-triazolo[4,5-e][1,3]diazepin-6-one, 3,4,5,8-tetrahydro-3-methyl-5-(sulfooxy)-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478626-64-1
CMF C7 H9 N5 O5 S



CM 2

CRN 121-44-8
CMF C6 H15 N



RN 478626-78-7 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-4-hydroxy-3-oxo-7-propoxy-, ethyl ester, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478626-81-2 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-7-hydroxy-3-oxo-4-(phenylmethoxy)-, ethyl ester, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478626-82-3 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-7-[(2-methoxyethoxy)methoxy]-3-oxo-4-(phenylmethoxy)-, ethyl ester, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478626-84-5 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-7-[(2-methoxyethoxy)methoxy]-3-oxo-4-(phenylmethoxy)-, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478626-85-6 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 1,3,4,5-tetrahydro-7-[(2-methoxyethoxy)methoxy]-3-oxo-4-(phenylmethoxy)-, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478626-86-7 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 1,3,4,5-tetrahydro-4-hydroxy-7-[(2-methoxyethoxy)methoxy]-3-oxo-, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478626-90-3 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-7-hydroxy-8-nitro-3-oxo-4-(phenylmethoxy)-, ethyl ester, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478626-91-4 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-7-[(2-methoxyethoxy)methoxy]-8-nitro-3-oxo-4-(phenylmethoxy)-, ethyl ester, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478626-93-6 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-7-[(2-methoxyethoxy)methoxy]-8-nitro-3-oxo-4-(phenylmethoxy)-, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478626-94-7 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 1,3,4,5-tetrahydro-7-[(2-methoxyethoxy)methoxy]-8-nitro-3-oxo-4-(phenylmethoxy)-, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478626-96-9 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 8-amino-1,3,4,5-tetrahydro-7-[(2-methoxyethoxy)methoxy]-3-oxo-4-(phenylmethoxy)-, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478626-97-0 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 8-(acetylamino)-1,3,4,5-tetrahydro-7-[(2-methoxyethoxy)methoxy]-3-oxo-4-(phenylmethoxy)-, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478626-99-2 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 8-(acetylamino)-1,3,4,5-tetrahydro-4-hydroxy-7-[(2-methoxyethoxy)methoxy]-3-oxo-, (1R,2S,5S)-rel-

(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478627-00-8 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxamide, 8-(acetylamino)-1,3,4,5-tetrahydro-7-[(2-methoxyethoxy)methoxy]-3-oxo-4-(sulfooxy)-, monosodium salt, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478627-23-5 CAPLUS
CN 6H-4,7-Methanoimidazo[4,5-e][1,3]diazepin-6-one, 1,4,5,8-tetrahydro-5-(phenylmethoxy)-1-[2-(phenylthio)ethyl]- (9CI) (CA INDEX NAME)



RN 478627-24-6 CAPLUS

CN 6H-4,7-Methanoimidazo[4,5-e][1,3]diazepin-6-one, 1,4,5,8-tetrahydro-5-(phenylmethoxy)-1-[2-(phenylsulfonyl)ethyl]- (9CI) (CA INDEX NAME)



RN 478627-25-7 CAPLUS
CN 1H-4,7-Methanoimidazo[4,5-e][1,3]diazepin-6-one, 1,4,5,8-tetrahydro-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 478627-26-8 CAPLUS
CN 1H-4,7-Methanoimidazo[4,5-e][1,3]diazepine-1-carboxylic acid, 4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 478627-27-9 CAPLUS
CN 1H-4,7-Methanoimidazo[4,5-e][1,3]diazepine-1-carboxylic acid, 4,5,6,8-tetrahydro-5-hydroxy-6-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 478627-47-3 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-3-oxo-6-(phenylmethoxy)-4-(2-propenyloxy)-, methyl ester, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478627-48-4 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-4-hydroxy-3-oxo-6-(phenylmethoxy)-, ethyl ester, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478627-51-9 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-9-carboxylic acid, 1,3,4,5-tetrahydro-4-hydroxy-3-oxo-6-propoxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 478627-53-1 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1-fluoro-1,3,4,5-tetrahydro-3-oxo-4-(2-propenyloxy)-, methyl ester (9CI) (CA INDEX NAME)



RN 478627-55-3 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepine-1-carboxylic acid, 1,3,4,5-tetrahydro-1-(methylthio)-3-oxo-4-(2-propenyloxy)-, methyl ester (9CI) (CA INDEX NAME)



RN 478627-63-3 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-8-methyl-6-oxo-5-(phenylmethoxy)-, methyl ester, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478627-64-4 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-5-hydroxy-8-methyl-6-oxo-, methyl ester, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478627-65-5 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-5-hydroxy-8-methyl-6-oxo-, methyl ester, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478627-66-6 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-8-methyl-6-oxo-5-(phenylmethoxy)-, methyl ester, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478627-68-8 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepin-3(1H)-one, 4,5-dihydro-1-(hydroxymethyl)-4-(2-propenyloxy)-, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478627-69-9 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepin-3(1H)-one, 4,5-dihydro-1-[(phenylmethoxy)methyl]-4-(2-propenyloxy)-, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478627-72-4 CAPLUS
CN 2,5-Methano-2H-2,4-benzodiazepin-3(1H)-one, 1-[[(aminocarbonyl)oxy]methyl]-4,5-dihydro-4-(2-propenyloxy)-, (1R,2S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478627-78-0 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-, methyl ester, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478627-79-1 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478627-80-4 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepin-6(5H)-one, 4,8-dihydro-8-(hydroxymethyl)-5-(phenylmethoxy)-, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478627-81-5 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepin-6(5H)-one, 4,8-dihydro-8-[[(methylsulfonyl)oxy]methyl]-5-(phenylmethoxy)-, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478627-82-6 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepin-6(5H)-one, 8-(azidomethyl)-4,8-dihydro-5-(phenylmethoxy)-, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478627-83-7 CAPLUS
CN Carbamic acid, [[(4R,7R,8R)-4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-4,7-methano-7H-thieno[2,3-e][1,3]diazepin-8-yl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478627-84-8 CAPLUS
CN Carbamic acid, [[(4R,7R,8R)-4,5,6,8-tetrahydro-5-hydroxy-6-oxo-4,7-methano-7H-thieno[2,3-e][1,3]diazepin-8-yl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478627-89-3 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide, 4,5,6,8-tetrahydro-N-methyl-6-oxo-5-(phenylmethoxy)-, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478627-90-6 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxamide, 4,5,6,8-tetrahydro-5-hydroxy-N-methyl-6-oxo-, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478628-04-5 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 1-ethyl-4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-, methyl ester, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478628-05-6 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 2-ethyl-2,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-, methyl ester, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478628-06-7 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 1-ethyl-4,5,6,8-tetrahydro-5-hydroxy-6-oxo-, methyl ester, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478628-09-0 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 2-ethyl-2,5,6,8-tetrahydro-5-hydroxy-6-oxo-, methyl ester, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478628-15-8 CAPLUS
CN Acetamide, N-[4,6,7,8-tetrahydro-6-oxo-7-(phenylmethoxy)-5,8-methano-5H-thiazolo[4,5-e][1,3]diazepin-2-yl]- (9CI) (CA INDEX NAME)



RN 478628-16-9 CAPLUS
CN Acetamide, N-(4,6,7,8-tetrahydro-7-hydroxy-6-oxo-5,8-methano-5H-thiazolo[4,5-e][1,3]diazepin-2-yl)- (9CI) (CA INDEX NAME)



RN 478628-18-1 CAPLUS
CN 1-Butanaminium, N,N,N-tributyl-, salt with N-[4,6,7,8-tetrahydro-6-oxo-7-(sulfooxy)-5,8-methano-5H-thiazolo[4,5-e][1,3]diazepin-2-yl]acetamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478628-17-0
CMF C9 H9 N4 O6 S2



CM 2

CRN 10549-76-5
CMF C16 H36 N



RN 478628-30-7 CAPLUS
CN 5,8-Methano-5H-thieno[2,3-e][1,3]diazepin-6(4H)-one, 7,8-dihydro-7-(2-propenyloxy)- (9CI) (CA INDEX NAME)



RN 478628-35-2 CAPLUS
CN 4,7-Methano-7H-isoxazolo[4,5-e][1,3]diazepin-6(5H)-one, 4,8-dihydro-5-(2-propenyloxy)- (9CI) (CA INDEX NAME)



RN 478628-44-3 CAPLUS
CN 5,8-Methano-8H-pyrido[2,3-e][1,3]diazepin-7(6H)-one, 5,9-dihydro-6-(2-propenyloxy)- (9CI) (CA INDEX NAME)



RN 478628-46-5 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 2,5,6,8-tetrahydro-2-methyl-6-oxo-5-(phenylmethoxy)-, methyl ester, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478628-47-6 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 2,5,6,8-tetrahydro-5-hydroxy-2-methyl-6-oxo-, methyl ester, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478628-50-1 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-2-iodo-6-oxo-5-(phenylmethoxy)-, methyl ester, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478628-51-2 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 2-ethenyl-4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-, methyl ester, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478628-52-3 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 2-ethyl-4,5,6,8-tetrahydro-5-hydroxy-6-oxo-, methyl ester, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478628-55-6 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-2-methyl-6-oxo-5-(phenylmethoxy)-, methyl ester, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478628-56-7 CAPLUS
CN 4,7-Methano-7H-thieno[2,3-e][1,3]diazepine-8-carboxylic acid, 4,5,6,8-tetrahydro-5-hydroxy-2-methyl-6-oxo-, methyl ester, (4R,7R,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478628-64-7 CAPLUS
CN Acetamide, N-[5,6,7,9-tetrahydro-7-oxo-6-(2-propenyloxy)-5,8-methano-8H-pyrimido[4,5-e][1,3]diazepin-2-yl]- (9CI) (CA INDEX NAME)



RN 478628-72-7 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 2-benzoyl-2,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)-, methyl ester, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478628-73-8 CAPLUS
CN 4H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid, 2-benzoyl-2,5,6,8-tetrahydro-5-hydroxy-6-oxo-, methyl ester, (4R,7R,8S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 478628-75-0 CAPLUS
CN 6H-4,7-Methanopyrazolo[3,4-e][1,3]diazepin-6-one, 1-(2,3-dihydroxypropyl)-1,4,5,8-tetrahydro-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 478628-76-1 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-1-acetaldehyde, 4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 478628-77-2 CAPLUS
CN 6H-4,7-Methanopyrazolo[3,4-e][1,3]diazepin-6-one, 1,4,5,8-tetrahydro-1-(2-hydroxyethyl)-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 478628-78-3 CAPLUS
CN 6H-4,7-Methanopyrazolo[3,4-e][1,3]diazepin-6-one, 1,4,5,8-tetrahydro-1-(2-iodoethyl)-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 478628-79-4 CAPLUS
CN 1H-4,7-Methanopyrazolo[3,4-e][1,3]diazepine-1-propanenitrile, 4,5,6,8-tetrahydro-6-oxo-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 478628-80-7 CAPLUS
CN 6H-4,7-Methanopyrazolo[3,4-e][1,3]diazepin-6-one, 1,4,5,8-tetrahydro-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 478628-81-8 CAPLUS
CN 6H-4,7-Methanopyrazolo[3,4-e][1,3]diazepin-6-one, 1,4,5,8-tetrahydro-5-hydroxy- (9CI) (CA INDEX NAME)



IT **478626-56-1P 478626-57-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of fused-ring diazepines, method of preparation and use as anti-bacterial agents)
RN 478626-56-1 CAPLUS
CN 6H-4,7-Methano-1,2,3-triazolo[4,5-e][1,3]diazepin-6-one, 1,4,5,8-tetrahydro-1-methyl-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 478626-57-2 CAPLUS
CN 6H-4,7-Methano-1,2,3-triazolo[4,5-e][1,3]diazepin-6-one, 3,4,5,8-tetrahydro-3-methyl-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



L10 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:123660 CAPLUS
DOCUMENT NUMBER: 136:325467
TITLE: Iodine(V) Reagents in Organic Synthesis. Part 3. New Routes to Heterocyclic Compounds via o-Iodoxybenzoic Acid-Mediated Cyclizations: Generality, Scope, and Mechanism
AUTHOR(S): Nicolaou, K. C.; Baran, P. S.; Zhong, Y.-L.; Barluenga, S.; Hunt, K. W.; Kranich, R.; Vega, J. A.
CORPORATE SOURCE: Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA
SOURCE: Journal of the American Chemical Society (2002), 124(10), 2233-2244
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 136:325467

AB N-aryl amides (anilides), carbamates, and ureas with pendant alkenes undergo o-iodoxybenzoic acid (IBX)-mediated radical cyclization reactions to give N-aryl δ-lactams, five-membered cyclic carbamates, and five-membered cyclic ureas in good yields. Amino alcs. are prepared by the cyclization of N-aryl carbamates followed by hydrolysis of the N-aryl cyclic carbamates with sodium hydroxide in ethanol. 1-Deoxy amino sugars, amino sugars, and amino sugar lactones can be prepared chemo- and stereoselectively from glycals by IBX-mediated cyclization of N-(4-methoxyphenyl) carbamates prepared from the hydroxy glycals followed by oxidative cleavage of the p-methoxyphenyl moieties and hydrolysis of the carbamates. The use of anhydrous IBX in THF leads to 1-deoxy amino sugar N-aryl carbamates as the sole products. The use of IBX in a THF:DMSO:H2O mixture leads to the N-aryl amino sugar carbamates, while the use of 4-6 equivalent of IBX in THF:H2O gives mixts. of the N-aryl amino sugar carbamates and the N-aryl amino sugar lactone carbamates. These procedures were used in a short synthesis of the amino sugar L-vancosamine. Hammett correlations of 4-substituted anilides, the rearrangement of an N-aryl diphenylcyclopropylpentenoyl amide during IBX-mediated cyclization, and studies of the oxidation potentials and cyclization rates of a set of N-aryl-N-(phenylthio) amides support a mechanism invoking single electron transfer from an anilide mol. to a solvent-activated mol. of IBX, followed by loss of a proton, radical 5-exo-trig cyclization, and loss of a hydrogen atom to produce the observed products. The cyclization of anilides to δ-lactams mediated by IBX can also be performed on solid phase.

IT **263546-59-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of cyclic N-aryl carbamates and ureas by IBX-mediated radical cyclizations of N-aryl carbamates and ureas)
RN 263546-59-4 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:107349 CAPLUS
DOCUMENT NUMBER: 136:167397
TITLE: Azabicyclic compounds, including 1,3-diazabicyclo[2.2.1]heptan-2-one and 1,6-diazabicyclo[3.2.1]octan-7-one derivatives, preparation thereof, and use as medicines, in particular as antibacterial agents
INVENTOR(S): Lampilas, Maxime; Aszodi, Jozsef; Rowlands, David Alun; Fromentin, Claude
PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr.
SOURCE: PCT Int. Appl., 146 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002010172	A1	20020207	WO 2001-FR2418	20010724
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2812635	A1	20020208	FR 2000-10121	20000801
FR 2812635	B1	20021011		
CA 2417475	AA	20020207	CA 2001-2417475	20010724
EP 1307457	A1	20030507	EP 2001-958173	20010724
EP 1307457	B1	20040407		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012986	A	20030708	BR 2001-12986	20010724
JP 2004505088	T2	20040219	JP 2002-515901	20010724
AT 263768	E	20040415	AT 2001-958173	20010724
PT 1307457	T	20040831	PT 2001-958173	20010724
EE 200300046	A	20041015	EE 2003-46	20010724
ES 2220793	T3	20041216	ES 2001-1958173	20010724
NZ 523707	A	20050225	NZ 2001-523707	20010724
CZ 294956	B6	20050413	CZ 2003-223	20010724
BG 107497	A	20030930	BG 2003-107497	20030123
ZA 2003000676	A	20040510	ZA 2003-676	20030124
US 2003199541	A1	20031023	US 2003-343315	20030129
NO 2003000494	A	20030328	NO 2003-494	20030131
US 2006046995	A1	20060302	US 2005-226749	20050914
PRIORITY APPLN. INFO.:			FR 2000-10121 A	20000801
			WO 2001-FR2418 W	20010724
			US 2003-343315 A1	20030129

OTHER SOURCE(S): MARPAT 136:167397
GI



I



II



III

AB The invention concerns novel heterocyclic compds. I and their addition salts with bases or acids [wherein: n = 1, 2; A = bond, =C(R4)-, -C(R4)=, -CH(R4)-; X = -C(O)Z- (bound at N with a C atom); Z = O, OCH2, NR8, NR8CH2, NR8O; R1 = H, CO2H, cyano, CO2R, CONR6R7, (CH2)1-2R5, C(:NR6)NHR7; R = (un)substituted alkyl, aryl, aralkyl, alkenylmethyl; R2 = H, (CH2)0-2R5; R3 = H, alkyl; R4 = H, (CH2)0-2R5; R5 = CO2H or derivs., cyano, OH or derivs., NH2 or derivs.; R6, R7 = H, (un)substituted alkyl, aryl, aralkyl, pyridylalkyl; R8 = H, OH or derivs., R, CO2H or derivs., numerous others; R1, R2, R3 are not H simultaneously]. The invention also concerns a method for preparing I, and their use as medicines, in particular as antibacterial agents. I have very good activity against gram-pos. bacteria such as staphylococci, and have notable activity against gram-neg. bacteria, particularly coliform bacteria. Over 50 synthetic examples are given. For instance, the cis-isomeric hydroxy ester II (preparation given) was converted to the triflate and treated with O-allylhydroxylamine to give a trans-isomeric propenyloxyamine derivative, which was de-N-trifluoroacetylated, cyclized with triphosgene, deallylated, sulfonated with SO3-pyridine, and ion-exchanged, to give a preferred title compound, III [X1 = O]. Another preferred compound, III [X1 = NH], had MIC values of 5 μg/mL against 2 strains of S. aureus (SG511 and Exp 54146).

IT **396730-16-8P**, 6-(Phenylmethyl)-1,6-diazabicyclo[3.2.1]octan-7-one **396730-24-8P**, 6-[1-(Phenylmethyl)-1H-tetrazol-5-yl]-1,6-diazabicyclo[3.2.1]octan-7-one **396730-27-1P**, 6-(Phenylmethoxy)-1,6-diazabicyclo[3.2.1]octan-7-one **396730-74-8P**, trans-Phenylmethyl 7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxylate 1-propenyltriphenylphosphonium salt **396730-85-1P**, trans-(4-Nitrophenyl)methyl 6-benzoyl-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylate **396730-93-1P**, trans-6-Benzoyl-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid **396731-02-5P**, trans-Phenylmethyl 6-benzoyl-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylate **396731-04-7P**, Phenylmethyl 6-benzoyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-ene-2-carboxylate **396731-07-0P**, trans-2-Propenyl 7-oxo-6-(phenylmethoxy)-1,6-diazabicyclo[3.2.1]octane-2-

carboxylate **396731-12-7P**, trans-7-Oxo-6-(phenylmethoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of azabicyclic compds. as antibacterial agents)

RN 396730-16-8 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 396730-24-8 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-[1-(phenylmethyl)-1H-tetrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 396730-27-1 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 396730-74-8 CAPLUS
CN Phosphonium, triphenyl-1-propenyl-, salt with rel-2-(phenylmethyl) (1R,2S,5R)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 396730-73-7
CMF C14 H15 N2 O7 S

Relative stereochemistry.



CM 2

CRN 76875-25-7
CMF C21 H20 P



RN 396730-85-1 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 6-benzoyl-7-oxo-, (4-nitrophenyl)methyl ester, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396730-93-1 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 6-benzoyl-7-oxo-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396731-02-5 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 6-benzoyl-7-oxo-, phenylmethyl ester, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396731-04-7 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]oct-2-ene-2-carboxylic acid, 6-benzoyl-7-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 396731-07-0 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 7-oxo-6-(phenylmethoxy)-, 2-propenyl ester, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396731-12-7 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 7-oxo-6-(phenylmethoxy)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **396730-18-0P**, 6-Benzoyl-1,6-diazabicyclo[3.2.1]octan-7-one **396730-20-4P**, 7-Oxo-1,6-diazabicyclo[3.2.1]octane-6-acetic acid **396730-23-7P**, 7-Oxo-N-phenyl-1,6-diazabicyclo[3.2.1]octane-6-carboxamide **396730-25-9P**, 6-(1H-Tetrazol-5-yl)-1,6-diazabicyclo[3.2.1]octan-7-one **396730-26-0P**, 6-Acetyl-1,6-diazabicyclo[3.2.1]octan-7-one **396730-32-8P**, 6-(Acetyloxy)-1,6-diazabicyclo[3.2.1]octan-7-one **396730-34-0P**, 6-(Benzoyloxy)-1,6-diazabicyclo[3.2.1]octan-7-one **396730-35-1P**, 6-(1-Oxopropoxy)-1,6-diazabicyclo[3.2.1]octane-7-one **396730-36-2P**, 6-[[(4-Methylphenyl)sulfonyl]oxy]-1,6-diazabicyclo[3.2.1]octan-7-one **396730-39-5P**, 6-[(Methylsulfonyl)oxy]-1,6-diazabicyclo[3.2.1]octan-7-one **396730-42-0P**, 6-[[(4-Nitrophenyl)sulfonyl]oxy]-1,6-diazabicyclo[3.2.1]octan-7-one **396730-45-3P**, 6-[[(4-Methylphenyl)sulfonyl]amino]-1,6-diazabicyclo[3.2.1]octan-7-one **396730-50-0P**, 6-[(4-Methylphenyl)sulfonyl]-1,6-diazabicyclo[3.2.1]octan-7-one **396730-80-6P**, trans-Phenylmethyl 7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxylate sodium salt **396730-81-7P**, trans-Phenylmethyl 7-oxo-6-[(phenylsulfonyl)oxy]-1,6-diazabicyclo[3.2.1]octane-2-carboxylate **396730-82-8P**, trans-Phenylmethyl 7-oxo-6-[(2-thienylsulfonyl)oxy]-1,6-diazabicyclo[3.2.1]octane-2-carboxylate **396730-83-9P**, trans-Phenylmethyl 6-(2-hydroxy-2-oxoethoxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylate **396730-94-2P**, trans-Methyl 6-benzoyl-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylate **396730-95-3P**, trans-6-Benzoyl-7-oxo-N-(phenylmethyl)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **396730-96-4P**, trans-6-Benzoyl-N-methyl-N-(phenylmethyl)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **396730-97-5P**, trans-6-Benzoyl-2-(hydroxymethyl)-1,6-diazabicyclo[3.2.1]octan-7-one **396730-98-6P**, trans-[(4-Nitrophenyl)methyl] 6-acetyl-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylate **396731-00-3P**, trans-(4-Nitrophenyl)methyl 2-propenyl 7-oxo-1,6-diazabicyclo[3.2.1]octane-2,6-dicarboxylate **396731-06-9P**, 6-Benzoyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-ene-2-carboxylic acid **396731-13-8P**, trans-7-Oxo-6-(phenylmethoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid cyclohexylamine salt **396731-14-9P**, trans-7-Oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **396731-15-0P**, trans-7-Oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide pyridinium salt **396731-19-4P**, trans-7-Oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide tetrabutylammonium salt **396731-20-7P**, trans-7-Oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide sodium salt **396731-21-8P**, trans-7-Oxo-N-(phenylmethyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide sodium salt **396731-22-9P**, trans-7-Oxo-N-(2-pyridinylmethyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide sodium salt **396731-23-0P**, trans-7-Oxo-N-[2-(3-pyridinyl)ethyl]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide sodium salt **396731-24-1P**, trans-7-Oxo-N-[2-(4-pyridinyl)ethyl]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide sodium salt **396731-25-2P**, trans-7-Oxo-N-[2-(2-pyridinyl)ethyl]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide sodium salt **396731-26-3P**, trans-N-[3-(Aminocarbonyl)phenyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide sodium salt **396731-27-4P**, trans-N-[4-(Dimethylamino)phenyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide sodium salt **396731-28-5P**, trans-N-[3-(Dimethylamino)phenyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide sodium salt

396731-29-6P, trans-7-Oxo-N-[(4-pyridinyl)methyl]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide sodium salt **396731-30-9P**, trans-7-Oxo-N-(3-pyridinylmethyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide sodium salt **396731-31-0P**, trans-N-(1-Amino-1-oxo-3-phenyl-2-propyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide sodium salt **396731-32-1P**, trans-N-(2-Amino-2-oxoethyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide sodium salt **396731-33-2P**, trans-N-[3-[(Aminocarbonyl)amino]phenyl]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide sodium salt **396731-34-3P**, trans-N-(2-Amino-2-oxo-1-phenylethyl)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide sodium salt **396731-35-4P**, trans-2-Amino-2-oxoethyl 7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxylate sodium salt **396731-36-5P**, trans-2-(4-Pyridinyl)ethyl 7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxylate sodium salt **396731-37-6P**, trans-2-(2-Pyridinyl)ethyl 7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxylate sodium salt **396731-38-7P**, trans-2-(3-Pyridinyl)ethyl 7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxylate sodium salt **396731-39-8P**, 3-Methoxy-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-3-en-7-one sodium salt **396731-55-8P**, 6-(Sulfooxy)-1,6-diazabicyclo[3.2.1]octan-7-one sodium salt **396731-63-8P**, trans-7-Oxo-N-(phenylmethyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **396731-64-9P**, trans-7-Oxo-N-(4-pyridinylmethyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **396731-65-0P**, trans-7-Oxo-N-(3-pyridinylmethyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **396731-66-1P**, trans-7-Oxo-N-(2-amino-2-oxoethyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **396731-67-2P**, trans-Phenylmethyl 7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxylate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of azabicyclic compds. as antibacterial agents)

RN 396730-18-0 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-benzoyl- (9CI) (CA INDEX NAME)



RN 396730-20-4 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-6-acetic acid, 7-oxo- (9CI) (CA INDEX NAME)



RN 396730-23-7 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-6-carboxamide, 7-oxo-N-phenyl- (9CI) (CA INDEX NAME)



RN 396730-25-9 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-(1H-tetrazol-5-yl)- (9CI) (CA INDEX NAME)



RN 396730-26-0 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-acetyl- (9CI) (CA INDEX NAME)



RN 396730-32-8 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-(acetyloxy)- (9CI) (CA INDEX NAME)



RN 396730-34-0 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-(benzoyloxy)- (9CI) (CA INDEX NAME)



RN 396730-35-1 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-(1-oxopropoxy)- (9CI) (CA INDEX NAME)



RN 396730-36-2 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-[[(4-methylphenyl)sulfonyl]oxy]- (9CI) (CA INDEX NAME)



RN 396730-39-5 CAPLUS

CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-[(methylsulfonyl)oxy]- (9CI) (CA INDEX NAME)



RN 396730-42-0 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-[[(4-nitrophenyl)sulfonyl]oxy]- (9CI) (CA INDEX NAME)



RN 396730-45-3 CAPLUS
CN Benzenesulfonamide, 4-methyl-N-(7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl)- (9CI) (CA INDEX NAME)



RN 396730-50-0 CAPLUS

CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 396730-80-6 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 7-oxo-6-(sulfooxy)-, 2-(phenylmethyl) ester, sodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396730-81-7 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 7-oxo-6-[(phenylsulfonyl)oxy]-, phenylmethyl ester, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396730-82-8 CAPLUS

CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 7-oxo-6-[(2-thienylsulfonyl)oxy]-, phenylmethyl ester, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396730-83-9 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 6-(carboxymethoxy)-7-oxo-, 2-(phenylmethyl) ester, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396730-94-2 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 6-benzoyl-7-oxo-, methyl ester, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396730-95-3 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 6-benzoyl-7-oxo-N-(phenylmethyl)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396730-96-4 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 6-benzoyl-N-methyl-7-oxo-N-(phenylmethyl)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396730-97-5 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-benzoyl-2-(hydroxymethyl)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396730-98-6 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 6-acetyl-7-oxo-, (4-nitrophenyl)methyl ester, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396731-00-3 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2,6-dicarboxylic acid, 7-oxo-, 2-[(4-nitrophenyl)methyl] 6-(2-propenyl) ester, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396731-06-9 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]oct-2-ene-2-carboxylic acid, 6-benzoyl-7-oxo- (9CI) (CA INDEX NAME)



RN 396731-13-8 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 7-oxo-6-(phenylmethoxy)-, (1R,2S,5R)-rel-, compd. with cyclohexanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 396731-12-7
CMF C14 H16 N2 O4

Relative stereochemistry.



CM 2

CRN 108-91-8
CMF C6 H13 N



RN 396731-14-9 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396731-15-0 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, (1R,2S,5R)-rel-, compd. with pyridine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 396731-14-9
CMF C7 H11 N3 O6 S

Relative stereochemistry.



CM 2

CRN 110-86-1
CMF C5 H5 N

RN 396731-19-4 CAPLUS
CN 1-Butanaminium, N,N,N-tributyl-, salt with rel-(1R,2S,5R)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 396731-18-3
CMF C7 H10 N3 O6 S

Relative stereochemistry.



CM 2

CRN 10549-76-5
CMF C16 H36 N



RN 396731-20-7 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-21-8 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 7-oxo-N-(phenylmethyl)-6-(sulfooxy)-, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-22-9 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 7-oxo-N-(2-pyridinylmethyl)-6-(sulfooxy)-, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-23-0 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 7-oxo-N-[2-(3-pyridinyl)ethyl]-6-(sulfooxy)-, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-24-1 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 7-oxo-N-[2-(4-pyridinyl)ethyl]-6-(sulfooxy)-, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-25-2 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 7-oxo-N-[2-(2-pyridinyl)ethyl]-6-(sulfooxy)-, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-26-3 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, N-[3-(aminocarbonyl)phenyl]-7-oxo-6-(sulfooxy)-, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-27-4 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, N-[4-(dimethylamino)phenyl]-7-oxo-6-(sulfooxy)-, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-28-5 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, N-[3-(dimethylamino)phenyl]-7-oxo-6-(sulfooxy)-, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-29-6 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 7-oxo-N-(4-pyridinylmethyl)-6-(sulfooxy)-, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-30-9 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 7-oxo-N-(3-pyridinylmethyl)-6-(sulfooxy)-, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-31-0 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, N-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-7-oxo-6-(sulfooxy)-, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-32-1 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, N-(2-amino-2-oxoethyl)-7-oxo-6-(sulfooxy)-, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-33-2 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, N-[3-[(aminocarbonyl)amino]phenyl]-7-oxo-6-(sulfooxy)-, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-34-3 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, N-(2-amino-2-oxo-1-phenylethyl)-7-oxo-6-(sulfooxy)-, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-35-4 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 7-oxo-6-(sulfooxy)-, 2-(2-amino-2-oxoethyl) ester, monosodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-36-5 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 7-oxo-6-(sulfooxy)-, 2-[2-(4-pyridinyl)ethyl] ester, sodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-37-6 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 7-oxo-6-(sulfooxy)-, 2-[2-(2-pyridinyl)ethyl] ester, sodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-38-7 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 7-oxo-6-(sulfooxy)-, 2-[2-(3-pyridinyl)ethyl] ester, sodium salt, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 396731-39-8 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]oct-3-en-7-one, 3-methoxy-6-(sulfooxy)-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 396731-55-8 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-(sulfooxy)-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 396731-63-8 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 7-oxo-N-(phenylmethyl)-6-(sulfooxy)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396731-64-9 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 7-oxo-N-(4-pyridinylmethyl)-6-(sulfooxy)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396731-65-0 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 7-oxo-N-(3-pyridinylmethyl)-6-(sulfooxy)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396731-66-1 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, N-(2-amino-2-oxoethyl)-7-oxo-6-(sulfooxy)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396731-67-2 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 7-oxo-6-(sulfooxy)-, 2-(phenylmethyl) ester, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **396730-21-5P**, 5-[(1,1-Dimethylethyl)dimethylsilyl]-1,6-diazabicyclo[3.2.1]octan-7-one **396730-22-6P**, Phenylmethyl 7-oxo-1,6-diazabicyclo[3.2.1]octane-6-acetate **396730-33-9P**, 6-Hydroxy-1,6-diazabicyclo[3.2.1]octan-7-one **396730-79-3P**, trans-Phenylmethyl 7-oxo-6-(2-propenyloxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxylate **396730-84-0P**, trans-Phenylmethyl 7-oxo-6-[2-oxo-2-(2-propenyloxy)ethoxy]-1,6-diazabicyclo[3.2.1]octane-2-carboxylate **396731-05-8P**, Phenylmethyl 6-benzoyl-7-oxo-2-(phenylselenyl)-1,6-diazabicyclo[3.2.1]octane-2-carboxylate **396731-16-1P**, trans-7-Oxo-6-(phenylmethoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **396731-17-2P**, trans-6-Hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide **396731-44-5P**, 3-Methoxy-6-(2-propenyloxy)-1,6-diazabicyclo[3.2.1]oct-3-en-7-one **396731-46-7P**, 3-Methoxy-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-3-en-7-one 1-propenyltriphenylphosphonium salt **396731-52-5P**, 6-(2-Propenyloxy)-1,6-diazabicyclo[3.2.1]oct-3-en-7-one **396731-54-7P**, 6-(Sulfooxy)-1,6-diazabicyclo[3.2.1]oct-3-en-7-one 1-propenyltriphenylphosphonium salt **396731-60-5P**, 6-(Phenylmethoxy)-1,6-diazabicyclo[3.2.1]oct-3-en-7-one **396731-62-7P**, 6-(Sulfooxy)-1,6-diazabicyclo[3.2.1]octan-7-one triethylammonium salt
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of azabicyclic compds. as antibacterial agents)

RN 396730-21-5 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 5-[(1,1-dimethylethyl)dimethylsilyl]- (9CI) (CA INDEX NAME)



RN 396730-22-6 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-6-acetic acid, 7-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 396730-33-9 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-hydroxy- (9CI) (CA INDEX NAME)



RN 396730-79-3 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 7-oxo-6-(2-propenyloxy)-, phenylmethyl ester, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396730-84-0 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 7-oxo-6-[2-oxo-2-(2-propenyloxy)ethoxy]-, phenylmethyl ester, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396731-05-8 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxylic acid, 6-benzoyl-7-oxo-2-(phenylseleno)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 396731-16-1 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 7-oxo-6-(phenylmethoxy)-,

(1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396731-17-2 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-2-carboxamide, 6-hydroxy-7-oxo-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396731-44-5 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]oct-3-en-7-one, 3-methoxy-6-(2-propenyloxy)- (9CI) (CA INDEX NAME)



RN 396731-46-7 CAPLUS
CN Phosphonium, triphenyl-1-propenyl-, salt with 3-methoxy-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-3-en-7-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 396731-45-6
CMF C7 H9 N2 O6 S



CM 2

CRN 76875-25-7
CMF C21 H20 P

$Ph_3{}^+P-CH=CH-Me$

RN 396731-52-5 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]oct-3-en-7-one, 6-(2-propenyloxy)- (9CI) (CA INDEX NAME)



RN 396731-54-7 CAPLUS
CN Phosphonium, triphenyl-1-propenyl-, salt with 6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-3-en-7-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 396731-53-6
CMF C6 H7 N2 O5 S



CM 2

CRN 76875-25-7
CMF C21 H20 P

$Ph_3{}^+P-CH=CH-Me$

RN 396731-60-5 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]oct-3-en-7-one, 6-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 396731-62-7 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-(sulfooxy)-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 396731-61-6
CMF C6 H10 N2 O5 S



CM 2

CRN 121-44-8
CMF C6 H15 N



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:152657 CAPLUS
DOCUMENT NUMBER: 134:178564
TITLE: Formation of heterocycles using o-iodoxybenzoic acid
INVENTOR(S): Nicolaou, Kyriacos C.; Zhong, Yong-li; Baran, Phillippe S.
PATENT ASSIGNEE(S): The Scripps Research Institute, USA
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001014348	A1	20010301	WO 2000-US22719	20000818
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 1999-150108P P 19990820
US 2000-493894 A 20000128
OTHER SOURCE(S): CASREACT 134:178564
GI


I


II


III


IV

AB Reaction of amide-containing alkenes with o-iodoxybenzoic acid gave complex heterocycles. Thus, unsatd, amides I and II were converted to heterocycles III (52% yield) and IV (95% yield), resp.

IT **263546-59-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(formation of heterocycles using o-iodoxybenzoic acid)
RN 263546-59-4 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:132435 CAPLUS
DOCUMENT NUMBER: 132:265132
TITLE: New synthetic technology for the rapid construction of novel heterocycles - part 2. The reaction of IBX with anilides and related compounds
AUTHOR(S): Nicolaou, K. C.; Zhong, Yong-Li; Baran, Phil S.
CORPORATE SOURCE: Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA
SOURCE: Angewandte Chemie, International Edition (2000), 39(3), 625-628
CODEN: ACIEF5; ISSN: 1433-7851
PUBLISHER: Wiley-VCH Verlag GmbH
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 132:265132
GI



I

AB IBX-promoted (IBX = o-iodoxybenzoic acid) cyclization of N-arylcarbamoyl alkenes, carbamates, thiocarbamates, and open-chain ureas led to a variety of heterocycles. E.g., IBX-promoted cyclization of 3-RC6H4NHCOCH2CH2CH:CH2 (R = H, Br, Et, F) gave lactams I. Also prepared were oxazolidinones, thiooxazolidinones, and cyclic ureas.

IT **263546-59-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of heterocycles by reaction of IBX with anilides and related compds.)
RN 263546-59-4 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one, 6-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:694549 CAPLUS
Correction of: 1991:492215
DOCUMENT NUMBER: 131:271857
Correction of: 115:92215
TITLE: 3-Aza- and syn-3,7-diazaoctabisvalene. Syntheses, x-ray structural analyses, novel heterocycles
AUTHOR(S): Trupp, Bjoern; Fritz, Hans; Prinzbach, Horst; Irngartinger, Hermann; Reifenstahl, Uwe
CORPORATE SOURCE: Inst. Org. Chem. Biochem., Univ. Freiburg, Freiburg, Germany
SOURCE: Chemische Berichte (1991), 124(8), 1777-1794
CODEN: CHBEAM; ISSN: 0009-2940
PUBLISHER: VCH
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 131:271857
GI



AB Preparatively useful routes for 3-aza- and syn-3,7-diazaoctabisvalenes were designed based on available materials. Thus, 7-cyano-3-azaoctabisvalene (I) becomes available in a six- (five-) step synthesis from the valence tautomers 7-cyanotropilidene .dblarw. 7-cyanonorcaradiene (derived dioxides) in an overall yield of ca. 30%, syn-3,7-diazaoctabisvalene (II) in a three-step synthesis from muco-diazidotetrol III in ca. 25% overall yield. For I and II spectroscopic (e.g. 15N-NMR resonances, 13C,C coupling consts.) and structural details (x-ray analyses) are determined I and II serve as starting materials for the construction of several novel heteropolycyclic skeletons, e.g. IV.

IT **122847-07-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 122847-07-8 CAPLUS
CN 2H-1,3,4-Metheno-1H-5-oxa-1a,3-diazacyclobuta[cd]pentalen-2-ol, tetrahydro-2-methyl- (9CI) (CA INDEX NAME)



L10 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1991:492215 CAPLUS
DOCUMENT NUMBER: 115:92215
TITLE: 3-Aza- and syn-3,7-diazaoctabisvalene. Syntheses, x-ray structural analyses, novel heterocycles
AUTHOR(S): Trupp, Bjoern; Fritz, Hans; Prinzbach, Horst
CORPORATE SOURCE: Inst. Org. Chem. Biochem., Univ. Freiburg i. Br., Freiburg, 7800, Germany
SOURCE: Chemische Berichte (1991), 124(8), 1777-94
CODEN: CHBEAM; ISSN: 0009-2940
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 115:92215
GI



I



II



III



IV

AB Preparatively useful routes for 3-aza- and syn-3,7-diazaoctabisvalenes were designed based on available materials. Thus, 7-cyano-3-azaoctabisvalene (I) becomes available in a six- (five-) step synthesis from the valence tautomers 7-cyanotropilidene .dblarw. 7-cyanonorcaradiene (derived dioxides) in an overall yield of ca. 30%, syn-3,7-diazaoctabisvalene (II) in a three-step synthesis from muco-diazidotetrol III in ca. 25% overall yield. For I and II spectroscopic (e.g. 15N-NMR resonances, 13C,C coupling consts.) and structural details (x-ray analyses) are determined I and II serve as starting materials for the construction of several novel heteropolycyclic skeletons, e.g. IV.

IT **122847-07-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 122847-07-8 CAPLUS
CN 2H-1,3,4-Metheno-1H-5-oxa-1a,3-diazacyclobuta[cd]pentalen-2-ol, tetrahydro-2-methyl- (9CI) (CA INDEX NAME)


OH
N
O
Me
N

L10 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1990:35577 CAPLUS
DOCUMENT NUMBER: 112:35577
TITLE: Azaoctabisvalene
AUTHOR(S): Trupp, Bjoern; Fritz, Hans; Prinzbach, Horst
CORPORATE SOURCE: Inst. Org. Chem. Biochem., Univ. Freiburg, Freiburg, D-7800, Fed. Rep. Ger.
SOURCE: Angewandte Chemie (1989), 101(10), 1381-3
CODEN: ANCEAD; ISSN: 0044-8249
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 112:35577
GI



I



II

AB A title compound, I, was prepared in several steps from epoxide II.
IT **122847-07-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 122847-07-8 CAPLUS
CN 2H-1,3,4-Metheno-1H-5-oxa-1a,3-diazacyclobuta[cd]pentalen-2-ol, tetrahydro-2-methyl- (9CI) (CA INDEX NAME)



L10 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1979:137719 CAPLUS
DOCUMENT NUMBER: 90:137719
TITLE: Stereoselective anticonvulsants: approaches to the synthesis of a bicyclic 2,4-oxazolidinedione and a bicyclic hydantoin
AUTHOR(S): Brouillette, Wayne Jason
CORPORATE SOURCE: Univ. Kansas, Lawrence, KS, USA
SOURCE: (1978) 209 pp. Avail.: Univ. Microfilms Int., Order No. 7824868
From: Diss. Abstr. Int. B 1979, 39(7), 3325
DOCUMENT TYPE: Dissertation
LANGUAGE: English
AB Unavailable
IT **68475-09-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation for use as anticonvulsant)
RN 68475-09-2 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-7,8-dione, 5-phenyl- (9CI) (CA INDEX NAME)



L10 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1979:121486 CAPLUS
DOCUMENT NUMBER: 90:121486
TITLE: N-Acylcarbamates as intermediates in synthetic approaches to a bicyclic trimethylene-bridged 2,4-oxazolidinedione and hydantoin
AUTHOR(S): Brouillette, Wayne J.; Smissman, Edward E.; Grunewald, Gary L.
CORPORATE SOURCE: Dep. Med. Chem., Univ. Kansas, Lawrence, KS, USA
SOURCE: Journal of Organic Chemistry (1979), 44(5), 839-43
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 90:121486
GI



I

AB The syntheses of the bicyclic 2,4-oxazolidinedione I (X = O) and bicyclic hydantoin I (X = NH) were attempted from several new N-acylcarbamates patterned after known precursors to monocyclic 2,4-oxazolidinediones. Heating 3-chloro-1-(ethoxycarbonyl)-3-phenyl-2-piperidinone resulted in ester pyrolysis and the reaction of 3-hydroxy-3-phenyl-2-piperidinone with ClCO2Et and K2CO3 yielded 1-(ethoxycarbonyl)-3-hydroxy-3-phenyl-2-piperidinone (II). The monocyclic analog of II, PhEt(HO)CCONMe(CO2Et), rapidly cyclized at room temperature to yield 5-ethyl-3-methyl-5-phenyl-2,4-oxazolidinedione, potentially representing a new, mild, neutral method for the synthesis of 2,4-oxazolidinediones. However, heating II resulted in decomposition or polymer formation, and the reaction of II with NaH resulted in an intramol. ethoxycarbonyl migration to give 3-(ethoxycarbonyloxy)-3-phenyl-2-piperidinone. An analogous approach to the bicyclic hydantoin I (X = NH) utilized 3-amino-1-(ethoxycarbonyl)-3-phenyl-2-piperidinone, but was also unsuccessful.

IT **68475-09-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(attempted preparation of)
RN 68475-09-2 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octane-7,8-dione, 5-phenyl- (9CI) (CA INDEX NAME)


O
N
HN
O
Ph

L10 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1959:77828 CAPLUS
DOCUMENT NUMBER: 53:77828
ORIGINAL REFERENCE NO.: 53:14121b-i,14122a-f
TITLE: Polymerization and ring strain in bridged bicyclic compounds
AUTHOR(S): Hall, H. K., Jr.
CORPORATE SOURCE: E. I. du Pont de Nemours & Co., Inc., Wilmington, DE
SOURCE: Journal of the American Chemical Society (1958), 80, 6412-20
CODEN: JACSAT; ISSN: 0002-7863
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
OTHER SOURCE(S): CASREACT 53:77828

AB A number of atom-bridged bicyclic compds. have been prepared to study their polymerizability. 3- and 4-H2N-C6H4CO2H hydrogenated over Ru-C in H2O gave the lactams of 3- and 4-H2NC6H10CO2H, m. 195-7° and 195-6°, resp. p-O2NC6H4CH2CO2H hydrogenated in aqueous solution over Ru2O gave p-H2NC6H10CH2CO2H (I), m. about 290°. I heated at 150 mm. with a drop of H3PO4, distilled, the distillates extracted with Et2O, and redistd., gave a mixture of an amide and a nitrile, b15 100-20°, and the lactam of I, m. 124°, identified by infrared analysis. Tetrahydrophthalimide on hydrogenolysis, distillation, and purification gave the lactam of cis-2-aminomethylcyclohexanecarboxylic acid, m. 77-8°. The lactam of cis-3-aminomethylcyclohexanecarboxylic acid could not be prepared by hydrogenolysis of 1,3-cyclohexanedicarboximide in dioxane over Ru2O, by partial reduction with LiAlH4 in tetrahydrofuran, or with H over Raney Ni in C6H12; partial hydrogenolysis was effected with Ni-C in dioxane with H, but the lactam could not be isolated. m-MeC6H4OH with COCl2 and PhNMe2 in C6H6 gave m-MeC6H4CO2Cl (II) b8 96°. m-H2NC6H4OH hydrogenated in H2O over Ru-C gave on distillation 25.5% mixed 3-H2NC6H10OH b0.5 115°; treatment with MeC6H4SO3H gave, after recrystn. a stereochemically impure salt, m. 150-2.2°. 3-NHAcC6H4OH (III) hydrogenated in EtOH over Ru2O gave cis-1,3-NHAcC6H10OH (IV), m. 118-18.5°. IV was also prepared by hydrogenation in EtOH over Pt2O overnight, warming with an infrared lamp. The hydrotosylate of IV, m. 155.5-6.5°, prepared by refluxing IV with MeC6H4SO3H.H2O in H2O 21 hrs. at 130° and precipitating in Me2CO. II and MgO in CHCl3 stirred 3 days, treated with 3N HCl and CHCl3, and the CHCl3 layer dried and evaporated, gave 88% N-m-cresyloxycarbonyl-cis-3-aminocyclohexanol, m. 133-7° (V). V, m-MeC6H4OH, and PbO refluxed 1 hr. at 150° gave the bicyclic urethan of cis-3-H2NC6H10OH, m. 151-2°. p-H2NC6H4OH hydrogenated in H2O over Ru-C and distilled gave a compound b0.5 90-108°; with Ac2O in CHCl3 a compound, m. 135.5-5.9° was obtained. The hydrotosylate of cis-4-H2NC6H10OH (VI), m. 197.5-8.5° was prepared similarly to the 3-isomer. VI, II, MgO, and CHCl3 stirred 3 days at room temperature, 3N HCl and CHCl3 added, the precipitate filtered off, and washed with 12N HCl and CHCl3, the H2O layer separated, extracted with CHCl3, and the CHCl3 evaporated gave the m-cresyloxycarbonyl derivative of cis-4-NH2C6H10OH (VII), m. 75.5-7.5°. VII was also prepared from VI, II, and K2CO3 in Me2CO. The bicyclic urethan of VI, m. 154-6°, was obtained similarly to the 1,3-isomer from VII. p-NHAcC6H4OH hydrogenated in absolute EtOH over Ru-C gave trans-4-NHAcC6H10OH (VIII), m. 160-3.5°. The hydrotosylate of VIII, prepared as described for the 3-isomer m. 243.5-45°; the m-cresyloxycarbonyl derivative (IX) m.

176-7°; the latter heated 15 min. at 200° with PbO gave a polymer, m. 400°, ηinh. (H2SO4) 0.08. p-H2NC6H10OH, b1.2 100-3°, was fractionally distilled, the fraction b20 132-5°, with II and K2CO3 in Me2CO-H2O gave, on recrystn. (CH2Cl2), IX, m. 174°; the CH2Cl2 filtrate, evaporated and heated with litharge, gave on sublimation at 120°/3 mm. pure bicyclic urethan. Hydrogenation of 3-HOC5H4N in H2O solution over Ru2O gave 82% 3-HOC5H9NH (X), m. 59-62°. II in CH2Cl2, added to X and Et3N in CH2Cl2, stirred 30 min., CH2Cl2 evaporated, Et2O added, the solution washed with 1N HCl and H2O, and evaporated gave 61.6% m-cresyloxycarbonyl derivative of X (XI), m. 62-4°. All attempts at preparation of the bicyclic urethan from XI resulted in decomposition 4-HOC5H9NH (XII), m. 85.5-8°, was prepared by hydrogenation of 4-HOC5H4N in H2O over Ru. XII and II with Et3N in CH2Cl2 gave 67.3% N-m-cresyloxycarbonyl derivative of XII, m. 84-6°, from which the bicyclic urethan of XII could not be readily prepared; this compound did not readily polymerize. Hydrogenation of m-C6H4(OH)2 in EtOH over Ru gave C6H11OH and the 1,3-diol (XIII), b1.4-1.0 107-10°. XIII, (EtO)2CO, and K2CO3 heated slowly to 200°, EtOH distilled, and the residue heated to 250° gave cyclohexane 1,3-diol cyclic carbonate (XIV), m. 173-4°. XIV and Cl2-C6H3SO3H heated 40 min. at 200°, the distillate treated with (CHCO)2O in Et2O, kept overnight at room temperature, extracted with 5:1 C7H16-C6H6, and the solvent evaporated gave the adduct of 1,3-cyclohexadiene with (CHCO)2O, m. 146-8°. 1,3-(H2N)2C6H10, (EtO)2CO, and NaH heated 2 hrs., EtOH distilled, and the residue sublimed at 210° gave 26% cyclic urea of 1,3-(H2N)2C6H10, m. 323°. cis-1,4-(H2N)2C6H10, similarly treated or on reaction with (PhO)2CO, gave no sublimable or H2O soluble material. 1,3-and 1,4-C6H10(CO2H)2 were prepared by hydrogenating 1,3- or 1,4-C6H4(CO2Me)2 in dioxane over RuC and hydrolyzing the esters by boiling 8 hrs. with 36% HCl. NH4OH (30%) added slowly to 1,3-C6H10(CO2H)2, H2O distilled slowly over 2 hrs., the residue distilled rapidly, H2O added, the pH brought to 7.0 with NaOH, CHCl3 added to the precipitate, CHCl3 evaporated from the total organic extract, and the residue sublimed, gave cyclohexane-1,3-carboximide (XV), m. 189-91°. A similar reaction with 40% aqueous MeNH2 gave 72.2% cyclohexane-1,3-dicarboxylic-N-methylimide, m. 58.5-9.5°. Cyclohexane-1,3-dicarboxylic anhydride prepared by the method of Perkin m. 167-86°. Hydrogenation of p-HOC6H4CO2H in H2O over Ru2O, and distillation of the acid at 190°/15 mm. gave the bicyclic lactone of 4-HOC6H10CO2H (XVI) m. 126-7°. Hydrogenation of m-HOC6H4CO2Et over Ru2O in EtOH gave 3-HOC6H10CO2Et (XVII) b0.5 90°. XVII heated 1 hr. at 190° with PbO, distilled in vacuo, and the residue recrystd. and sublimed, gave the 3-isomer of XVI, m. 126-31°. Polymerization of bicyclic monomers was carried out as previously described (cf. two preceding abstract). Cyclic ester, urethans, and imides were heated 24 hrs. at 100-200° with PbO, K2CO3, NaH, tetraisopropyl titanate, and 2,5-Cl2C6H3SO3H. Lactones and cyclic ureas were heated 24 hrs. at 150-260° with H2O and NaH. Polymerization results show that different kinds of monomers belonging to a given ring system show common behavior. Compds. belonging to the bicyclo [2.2.2]octane and bicyclo [3.2.2] nonane series, in which the cyclohexane ring occurs in the boat form, underwent polymerization readily. Monomers of the bicyclo[3.2.1]octane group differed in ease of polymerization. Compds. of the bicyclo [3.3.1] nonane series, in which 2 stable chair forms of cyclohexane are fused together, were not polymerizable.

IT **101080-06-2**, 1,6-Diazabicyclo[3.2.1]octan-7-one
(theoretical probability of existence of)

RN 101080-06-2 CAPLUS
CN 1,6-Diazabicyclo[3.2.1]octan-7-one (6CI) (CA INDEX NAME)